Venetoclax Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Venetoclax comprises 654 peer-reviewed publications across 15 journals, 28 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, and Multiple Myeloma. Most recent publication: A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol., EJHaem, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.
    Wolff D, Cutler C, Lee SJ, et al. · N Engl J Med · 2024
    PubMed: PMID 39292927 · NCT07511062 · Leukemia, Myeloid, Acute
  2. A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol.
    Palmisiano ND, Lee JW, Claxton DF, et al. · EJHaem · 2026
    PubMed: PMID 39415930 · NCT03504644 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  3. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.
    Lindsley RC, Saber W, Mar BG, et al. · N Engl J Med · 2017
    PubMed: PMID 28177873 · NCT06337331 · Leukemia, Myeloid, Acute
  4. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
    Fürstenau M, Kater AP, Robrecht S, et al. · Lancet Oncol · 2024
    PubMed: PMID 38821083 · NCT02950051 (GAIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  5. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
    Eichhorst B, Niemann CU, Kater AP, et al. · N Engl J Med · 2023
    PubMed: PMID 37163621 · NCT02950051 (GAIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  6. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
    DiNardo CD, Jonas BA, Pullarkat V, et al. · N Engl J Med · 2020
    PubMed: PMID 32786187 · NCT06571825 · Leukemia, Myeloid, Acute
  7. Department of Error.
    Lancet · 2023
    PubMed: PMID 37838437 · NCT06561880 (FLT3AML-2024)
  8. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
    Cramer P, Fürstenau M, Robrecht S, et al. · Lancet Haematol · 2022
    PubMed: PMID 35988545 · NCT03787264 (CLL2-BAAG) · Leukemia, B-Cell

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT02005471
MURANO
Leukemia, Lymphocytic, Chronic, B-CellPercentage of Participants With PD as Assessed by the Investigator Using Standard International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines or Death
Baseline up to PD or death from any cause, whichever occurred first (up to approximately 8 years 5 months)
Bendamustine + Rituximab Main Study88.7 percentage of participants
Venetoclax + Rituximab Main Study70.1 percentage of participants
NCT02005471
MURANO
Leukemia, Lymphocytic, Chronic, B-CellProgression-Free Survival (PFS) as Assessed by the Investigator Using Standard iwCLL Guidelines
Baseline up to PD or death, whichever occurred first (up to approximately 8 years 5 months)
Bendamustine + Rituximab Main Study17.0 months
Venetoclax + Rituximab Main Study54.7 months
NCT02242942Leukemia, Lymphocytic, Chronic, B-CellProgression Free Survival (PFS) Based on Investigator Assessment According to IWCLL Criteria
Baseline until disease progression or death up to approximately 3.75 years
Obinutuzumab + ChlorambucilNA months
Obinutuzumab + VenetoclaxNA months
NCT02755597
Bellini
Multiple MyelomaProgression-free Survival (PFS)
Median duration of follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group
Placebo + Bortezomib and Dexamethasone11.5 months
Venetoclax + Bortezomib and Dexamethasone23.2 months
NCT02756611
VENICE I
Leukemia, Lymphocytic, Chronic, B-CellComplete Remission Rate in Participants Not Previously Treated With BCRi Therapy - Primary Analysis
From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.
Venetoclax35.1 percentage of participants
NCT02980731
VENICE II
Leukemia, Lymphocytic, Chronic, B-CellMean Change From Baseline to Week 48 in Global Health Status/Quality of Life (GHS/QoL) Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
Baseline, Week 48
Venetoclax9.3 units on a scale (±20.11 Standard Deviation)
NCT02993523
Viale-a
Leukemia, Myeloid, AcuteOverall Survival (OS)
From the study start up to death or alive or lost to follow-up (up to approximately 4.8 years; data cut off date: 1 December 2021)
Group 2: Placebo + Azacitidine 75 mg/m^29.6 months
Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^214.7 months
NCT02993523
Viale-a
Leukemia, Myeloid, AcutePercentage of Participants With Complete Remission (CR) and Complete Remission With Incomplete Marrow Recovery (CRi)
From the study start up to death (up to approximately 4.8 years; data cut-off date: 1 December 2021)
Group 2: Placebo + Azacitidine 75 mg/m^217.9 percentage of participants
Group 2: Placebo + Azacitidine 75 mg/m^211.0 percentage of participants
Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^228.0 percentage of participants
Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^238.8 percentage of participants
Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^220.0 percentage of participants
Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^260.0 percentage of participants
NCT03069352Leukemia, Myeloid, AcuteOverall Survival (OS)
From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.
Placebo + Low Dose Cytarabine (LDAC)4.1 months
Venetoclax + Low Dose Cytarabine (LDAC)7.2 months
NCT03112174
SYMPATICO
Lymphoma, Non-HodgkinComplete Response (CR) Rate (Treatment-Naive Arm)
For an overall median time on study of 40.51 months
Treatment-naive Open-label Arm69.2 percentage of participants
NCT03112174
SYMPATICO
Lymphoma, Non-HodgkinNumber of Participants With Dose Limiting Toxicities (DLT) (Safety Run-in)
After at least 3 months of treatment, with an overall median treatment duration of 20.0 months
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline0 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline0 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline0 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline3 Participants
Safety Run-in: Increased TLS Risk at Baseline3 Participants
Safety Run-in: Increased TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
NCT03112174
SYMPATICO
Lymphoma, Non-HodgkinNumber of Participants With Treatment Emergent Adverse Events (TEAEs) (Safety Run-in)
From first dose of study drug until the end of treatment + 30 days, with an overall median treatment duration of 20.0 months
Safety Run-in: Increased TLS Risk at Baseline10 Participants
Safety Run-in: Increased TLS Risk at Baseline2 Participants
Safety Run-in: Increased TLS Risk at Baseline2 Participants
Safety Run-in: Increased TLS Risk at Baseline2 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline10 Participants
Safety Run-in: Increased TLS Risk at Baseline15 Participants
Safety Run-in: Increased TLS Risk at Baseline15 Participants
Safety Run-in: Increased TLS Risk at Baseline14 Participants
Safety Run-in: Increased TLS Risk at Baseline13 Participants
Safety Run-in: Increased TLS Risk at Baseline13 Participants
Safety Run-in: Increased TLS Risk at Baseline12 Participants
Safety Run-in: Increased TLS Risk at Baseline6 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline4 Participants
Safety Run-in: Increased TLS Risk at Baseline7 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline3 Participants
Safety Run-in: Increased TLS Risk at Baseline3 Participants
Safety Run-in: Increased TLS Risk at Baseline14 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline0 Participants
Safety Run-in: Increased TLS Risk at Baseline13 Participants
Safety Run-in: Increased TLS Risk at Baseline14 Participants
Safety Run-in: Increased TLS Risk at Baseline14 Participants
Safety Run-in: Increased TLS Risk at Baseline9 Participants
Safety Run-in: Low TLS Risk at Baseline5 Participants
Safety Run-in: Low TLS Risk at Baseline4 Participants
Safety Run-in: Low TLS Risk at Baseline1 Participants
Safety Run-in: Low TLS Risk at Baseline2 Participants
Safety Run-in: Low TLS Risk at Baseline3 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline4 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline2 Participants
Safety Run-in: Low TLS Risk at Baseline2 Participants
Safety Run-in: Low TLS Risk at Baseline1 Participants
Safety Run-in: Low TLS Risk at Baseline6 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline4 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline1 Participants
Safety Run-in: Low TLS Risk at Baseline1 Participants
Safety Run-in: Low TLS Risk at Baseline1 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline4 Participants
Safety Run-in: Low TLS Risk at Baseline6 Participants
Safety Run-in: Low TLS Risk at Baseline3 Participants
Safety Run-in: Low TLS Risk at Baseline5 Participants
Safety Run-in: Low TLS Risk at Baseline3 Participants
NCT03112174
SYMPATICO
Lymphoma, Non-HodgkinNumber of Participants With Tumor Lysis Syndrome (TLS) Events (Safety Run-in)
After at least 3 months of treatment, with an overall median treatment duration of 20.0 months
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
NCT03112174
SYMPATICO
Lymphoma, Non-HodgkinProgression-free Survival (PFS) (Randomization Phase)
For an overall median time on study of 61.34 months
Randomization Phase: Ibrutinb + Venetoclax31.9 months
Randomization Phase: Ibrutinib + Placebo22.1 months
NCT03336333
SEQUOIA
Leukemia, Lymphocytic, Chronic, B-CellCohort 1: Progression-free Survival (PFS) as Determined by Independent Central Review (ICR)
Up to approximately 3 years and 7 months (as of cut-off date of 07MAY2021)
Cohort 1: Bendamustine + Rituximab Without Del(17p)33.7 Months
Cohort 1: Zanubrutinib Without Del(17p)NA Months
NCT03406156Leukemia, Lymphocytic, Chronic, B-CellComplete Remission Rate
From first dose of study drug until the last participant completed Week 65 assessments (data cut-off date of 13 October 2021); overall median time on follow-up was up to 787 days
Obinutuzumab51.2 percentage of participants
Obinutuzumab/Bendamustine16.7 percentage of participants
NCT03406156Leukemia, Lymphocytic, Chronic, B-CellPercentage of Participants Achieving Low Tumor Burden Status With Induction of Obinutuzumab or Obinutuzumab Plus Bendamustine (Debulking Period)
From Baseline to the end of Cycles 2, 4, and 6, up to approximately 24 weeks after initial dose of study drug
Obinutuzumab81.4 percentage of participants
Obinutuzumab95.0 percentage of participants
Obinutuzumab88.3 percentage of participants
Obinutuzumab/Bendamustine83.9 percentage of participants
Obinutuzumab/Bendamustine90.3 percentage of participants
Obinutuzumab/Bendamustine87.1 percentage of participants
NCT03462719
GLOW
Leukemia, Lymphocytic, Chronic, B-CellProgression Free Survival (PFS)
Up to 2 years 10 months
Treatment Arm A (Ibrutinib + Venetoclax)NA Months
Treatment Arm B (Chlorambucil + Obinutuzumab)20.96 Months
NCT03737981Leukemia, Lymphocytic, Chronic, B-CellProgression-free Survival (PFS)
5 years
Arm I (Ibrutinib, Obinutuzumab)0.59 proportion of participants w/out event
Arm II (Ibrutinib, Obinutuzumab, Venetoclax)0.68 proportion of participants w/out event
NCT03801525
ULTRA-V
Leukemia, Lymphocytic, Chronic, B-CellPhase 2: Complete Response (CR) Rate as Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 Criteria
Up to 43.2 months
Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V)33.6 percentage of participants
NCT03801525
ULTRA-V
Leukemia, Lymphocytic, Chronic, B-CellPhase 2: Overall Response Rate (ORR) Per iwCLL 2018 Criteria
Up to 43.2 months
Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V)93.3 percentage of participants
NCT03801525
ULTRA-V
Leukemia, Lymphocytic, Chronic, B-CellPhase 3: Progression-Free Survival (PFS) Per iwCLL 2018 Criteria
Up to 43.2 months
Phase 3: Ublituximab + Umbralisib (U2)NA months
Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V)NA months
NCT03941964Leukemia, Myeloid, AcutePercentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi)
Assessed at Cycle 1 end, at Cycle 2 end if CR/CRi wasn't achieved at Cycle 1 end, or Cycle 4 end if CR/CRi wasn't achieved at Cycle 2 end. Median treatment duration of venetoclax was 16.1 wks (range 3.9-38.1) and 21.1 wks (range 2.7-40.4), respectively.
Venetoclax 400 mg + Azacitidine 75 mg70.0 percentage of participants
Venetoclax 400 mg + Decitabine 20 mg63.3 percentage of participants
NCT04102020
VIALE-M
Leukemia, Myeloid, AcuteNumber of Participants With DLTs of Venetoclax in Combination With Oral AZA (Part 3 Dose Finding Portion)
Up to 28 days (Cycle 1)
Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mg0 Participants
Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mg1 Participants
Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mg0 Participants
Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mg1 Participants
Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mg1 Participants
Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mg0 Participants
Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mg1 Participants
Part 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg1 Participants
Part 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg2 Participants
Part 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg1 Participants
Part 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg1 Participants
Part 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg1 Participants
Part 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg0 Participants
Part 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg1 Participants
NCT04102020
VIALE-M
Leukemia, Myeloid, AcuteNumber of Participants With Dose-Limiting Toxicities (DLTs) of Venetoclax in Combination With Azacitidine (AZA) (Part 1)
Up to 28 days (Cycle 1)
Part 1: Venetoclax 400 mg + Azacitidine 20 mg/m^21 Participants
Part 1: Venetoclax 400 mg + Azacitidine 20 mg/m^21 Participants
Part 1: Venetoclax 400 mg + Azacitidine 20 mg/m^21 Participants
Part 1: Venetoclax 400 mg + Azacitidine 20 mg/m^23 Participants
Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^20 Participants
Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^24 Participants
Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^20 Participants
Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^20 Participants
Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^20 Participants
Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^20 Participants
Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^20 Participants
Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^24 Participants
NCT04285567
CRISTALLO
Leukemia, Lymphocytic, Chronic, B-CellMinimal Residual Disease (MRD) Response Rate Measured in Peripheral Blood (PB) Using Next Generation Sequencing (NGS)
At Month 15
Arm A: VEN+G81.3 percentage of participants
Arm B: FCR/BR54.7 percentage of participants
NCT04778397
ENHANCE-2
Leukemia, Myeloid, AcuteOverall Survival (OS) in Participants Appropriate for Non-intensive Therapy
Up to 2.1 years
Control Arm: Venetoclax + Azacitidine (Non-Intensive Therapy)6.6 months
Magrolimab + Azacitidine (Non-Intensive Therapy)4.4 months
NCT05079230
ENHANCE-3
Leukemia, Myeloid, AcuteOverall Survival (OS)
Up to 1.6 years
Magrolimab + Venetoclax + Azacitidine10.7 months
Magrolimab Matching Placebo + Venetoclax + Azacitidine14.1 months

Publications by year

1984–2026: 654 publications.

1984
1
1988
1
1989
1
1990
1
1994
5
1996
2
1997
1
1998
5
1999
3
2001
3
2002
4
2003
4
2004
2
2005
3
2006
7
2007
5
2008
6
2009
11
2010
10
2011
11
2012
12
2013
13
2014
20
2015
19
2016
16
2017
30
2018
21
2019
40
2020
48
2021
62
2022
77
2023
56
2024
64
2025
63
2026
27

Publications by indication

Leukemia, Myeloid, Acute (386)

  • Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional "3 + 7" intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial.
    Trials · 2026 · PMID 41366419 · NCT06451861
  • Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia.
    Blood Neoplasia · 2026 · PMID 42007248 · NCT06014489
  • Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.
    Blood Adv · 2026 · PMID 41269778 · NCT02287233
  • Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.
    Blood Adv · 2026 · PMID 42200455 · NCT04140487
  • Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.
    Lancet Haematol · 2026 · PMID 41791831 · NCT04330820

Leukemia, Lymphocytic, Chronic, B-Cell (85)

  • Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.
    Blood Adv · 2026 · PMID 41544219 · NCT03740529
  • Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.
    Lancet Haematol · 2026 · PMID 42069409 · NCT03740529
  • Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial.
    Lancet Haematol · 2026 · PMID 41380698 · NCT04623541
  • Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.
    Blood · 2026 · PMID 41911073 · NCT02950051
  • A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation.
    Blood Adv · 2026 · PMID 41886642 · NCT03534323

Precursor Cell Lymphoblastic Leukemia-Lymphoma (61)

  • A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol.
    EJHaem · 2026 · PMID 39415930 · NCT03504644
  • Venetoclax Plus Pediatric Regimen in Adolescents and Adults with Ph-Negative Acute Lymphoblastic Leukemia.
    Blood · 2026 · PMID 42166560 · NCT05660473
  • Immunotherapy in B-Cell Acute Lymphoblastic Leukemia.
    J Natl Compr Canc Netw · 2026 · PMID 41671463 · NCT06387121
  • How I treat ETP-ALL in children.
    Blood · 2025 · PMID 38364183 · NCT06855810
  • A new chemotherapy-free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study.
    Am J Hematol · 2024 · PMID 38482543 · NCT06754267

Multiple Myeloma (14)

  • Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study.
    Lancet Haematol · 2025 · PMID 40587991 · NCT02755597
  • Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety.
    Hematol Oncol · 2024 · PMID 37740931 · NCT01794520
  • Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma.
    Clin Lymphoma Myeloma Leuk · 2022 · PMID 36450626 · NCT03312530
  • Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
    Lancet · 2022 · PMID 34097854 · NCT06115135
  • Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
    Lancet Oncol · 2021 · PMID 33129376 · NCT02755597

Lymphoma, Non-Hodgkin (10)

  • Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403.
    Blood Cancer J · 2025 · PMID 40355425 · NCT03113422
  • Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet Oncol · 2025 · PMID 39914418 · NCT03112174
  • Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.
    N Engl J Med · 2024 · PMID 38899693 · NCT03223610
  • MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.
    Blood Adv · 2024 · PMID 38113470 · NCT03505944
  • Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription.
    Cancer Res Commun · 2023 · PMID 37882668 · NCT05371054

Recurrence (10)

  • Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.
    J Clin Oncol · 2026 · PMID 41370738 · NCT03539744
  • Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial.
    Lancet Haematol · 2025 · PMID 41338863 · NCT05149378
  • Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients.
    Invest New Drugs · 2024 · PMID 39388024 · NCT02899052
  • A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.
    Clin Lymphoma Myeloma Leuk · 2022 · PMID 34551886 · NCT03567616
  • Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Blood Adv · 2021 · PMID 34470049 · NCT02899052

Publications by journal

Trial-results highlights

In studies of chronic lymphocytic leukemia (CLL), the MURANO trial (NCT02005471) evaluated venetoclax plus rituximab. In this study, the percentage of participants with disease progression or death was 70.1% in the Venetoclax + Rituximab arm, compared to 88.7% in the Bendamustine + Rituximab arm. Progression-free survival (PFS) was a median of 54.7 months in the Venetoclax + Rituximab arm, versus a median of 17.0 months in the Bendamustine + Rituximab arm. For participants with CLL not previously treated with BCRi therapy, the VENICE I study (NCT02756611) reported a complete remission rate of 35.1% in the Venetoclax arm. In the VENICE II study (NCT02980731), the Venetoclax arm showed a mean change from baseline to Week 48 in global health status/quality of life of 9.3 units on a scale.

For multiple myeloma, the Bellini study (NCT02755597) reported a median progression-free survival of 23.2 months in the Venetoclax + Bortezomib and Dexamethasone arm, compared to 11.5 months in the Placebo + Bortezomib and Dexamethasone arm. In acute myeloid leukemia (AML), the Viale-a study (NCT02993523) reported a median overall survival of 14.7 months in the Venetoclax + Azacitidine arm, versus 9.6 months in the Placebo + Azacitidine arm. The percentage of participants with complete remission (CR) and complete remission with incomplete marrow recovery (CRi) in Viale-a (NCT02993523) was:

  • In the Placebo + Azacitidine arm, CR was 17.9% and CRi was 11.0%.
  • In the Venetoclax + Azacitidine arm, CR was 28.0% and CRi was 38.8%.
  • In the Open Label China Cohort (Venetoclax + Azacitidine), CR was 20.0% and CRi was 60.0%.

All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Venetoclax publications (654)

2026 (27 papers)

  1. A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol.
    Palmisiano ND, Lee JW, Claxton DF, et al. · EJHaem · 2026 · Trial result
    PubMed: PMID 39415930 · NCT03504644 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  2. Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional "3 + 7" intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial.
    Yan H, Huang X, Wu P, et al. · Trials · 2026 · Derived
    PubMed: PMID 41366419 · NCT06451861 · Leukemia, Myeloid, Acute
  3. Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia.
    Westra N, Cerro ER, Schilder E, et al. · Blood Neoplasia · 2026 · Derived
    PubMed: PMID 42007248 · NCT06014489 (HO171) · Leukemia, Myeloid, Acute
  4. Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.
    Wei AH, Panayiotidis P, Montesinos P, et al. · Blood Adv · 2026 · Derived
    PubMed: PMID 41269778 · NCT02287233 · Leukemia, Myeloid, Acute
  5. Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.
    Short NJ, Kantarjian HM, Daver NG, et al. · Blood Adv · 2026 · Derived
    PubMed: PMID 42200455 · NCT04140487 · Leukemia, Myeloid, Acute
  6. Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.
    Ruhnke L, Schliemann C, Mikesch JH, et al. · Lancet Haematol · 2026 · Derived
    PubMed: PMID 41791831 · NCT04330820 (RELAX) · Leukemia, Myeloid, Acute
  7. Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I/II, Multicenter, Multi-arm Study.
    Rubio-San-Simón A, Marshall LV, Doz F, et al. · Target Oncol · 2026 · Derived
    PubMed: PMID 41379293 · NCT04029688 · Leukemia, Myeloid, Acute
  8. Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm.
    Raychaudhuri S, Gooley TA, Rasmussen A, et al. · Blood Neoplasia · 2026 · Derived
    PubMed: PMID 40535475 · NCT04797767 · Leukemia, Myeloid, Acute
  9. Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.
    Popat R, Beksac M, Dimopoulos MA, et al. · J Clin Oncol · 2026 · Derived
    PubMed: PMID 41370738 · NCT03539744 · Recurrence
  10. Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.
    Patel K, Vose JM, Nasta SD, et al. · Blood Adv · 2026 · Derived
    PubMed: PMID 41544219 · NCT03740529 · Leukemia, Lymphocytic, Chronic, B-Cell
  11. Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.
    Palomba ML, Patel MR, Eyre TA, et al. · Lancet Haematol · 2026 · Derived
    PubMed: PMID 42069409 · NCT03740529 · Leukemia, Lymphocytic, Chronic, B-Cell
  12. Integration of venetoclax into a fludarabine and melphalan conditioning regimen in patients aged 50 years and older with acute myeloid leukemia and myelodysplastic syndrome: Results from a phase 2 clinical trial.
    Lai X, Zhu P, Yang L, et al. · Cancer · 2026 · Derived
    PubMed: PMID 42159161 · NCT05084027 · Hematologic Neoplasms
  13. Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial.
    Kater AP, Janssens A, Eradat H, et al. · Lancet Haematol · 2026 · Derived
    PubMed: PMID 41380698 · NCT04623541 (EPCORE™ CLL-1) · Leukemia, Lymphocytic, Chronic, B-Cell
  14. Anexelekto (Axl)/Mer Inhibitor Tamnorzatinib in Patients with Relapsed/Refractory Acute Myeloid Leukaemia: Results from a Phase I (Monotherapy) and Phase II (Combination with Venetoclax) Clinical Study.
    Kasner MT, Courtenay-Luck N, DiNardo C, et al. · Acta Haematol · 2026 · Derived
    PubMed: PMID 41385448 · NCT03176277 · Leukemia, Myeloid, Acute
  15. Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.
    Kadia TM, Bataller A, Bazinet A, et al. · Am J Hematol · 2026 · Derived
    PubMed: PMID 42035228 · NCT03586609 · Leukemia, Myeloid, Acute
  16. Venetoclax Plus Pediatric Regimen in Adolescents and Adults with Ph-Negative Acute Lymphoblastic Leukemia.
    Gong X, Liu Y, Fang Q, et al. · Blood · 2026 · Derived
    PubMed: PMID 42166560 · NCT05660473 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  17. High-Throughput Proteomic Profiling to Evaluate Differentiation Syndrome With Menin Inhibition.
    Garcia MB, Wang B, Sheikh I, et al. · Mol Cell Proteomics · 2026 · Derived
    PubMed: PMID 41621809 · NCT05360160 · Leukemia, Myeloid, Acute
  18. Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML.
    Garcia JS, Kim HT, Murdock HM, et al. · Blood Adv · 2026 · Derived
    PubMed: PMID 41348911 · NCT03613532 · Leukemia, Myeloid, Acute
  19. Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.
    Fürstenau M, Niemann CU, Robrecht S, et al. · Blood · 2026 · Derived
    PubMed: PMID 41911073 · NCT02950051 (GAIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  20. Low dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: A phase 2 study.
    De la Garza-Salazar F, Colunga-Pedraza PR, Gómez-Almaguer D, et al. · Leuk Res · 2026 · Derived
    PubMed: PMID 37633156 · NCT05048615 · Leukemia, Myeloid, Acute
  21. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia.
    Davis KL, Yao CC, Zimmerman JAO, et al. · J Natl Compr Canc Netw · 2026 · Derived
    PubMed: PMID 41671463 · NCT06387121 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  22. A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation.
    Crombie JL, Ryan CE, Ren Y, et al. · Blood Adv · 2026 · Derived
    PubMed: PMID 41886642 · NCT03534323 · Leukemia, Lymphocytic, Chronic, B-Cell
  23. Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
    Brown JR, Nguyen B, Desikan SP, et al. · Blood · 2026 · Derived
    PubMed: PMID 41055698 · NCT03740529 · Leukemia, Lymphocytic, Chronic, B-Cell
  24. Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.
    Borate U, Tognon CE, Madanat YF, et al. · Blood Neoplasia · 2026 · Derived
    PubMed: PMID 42007254 · NCT03874052 · Leukemia, Myeloid, Acute
  25. Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
    Ball S, Awan FT, Tomlinson BK, et al. · Am J Hematol · 2026 · Derived
    PubMed: PMID 41796974 · NCT03955783 · Leukemia, Myeloid, Acute
  26. A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia.
    Aribi A, Mannis GN, Madanat YF, et al. · Blood Neoplasia · 2026 · Derived
    PubMed: PMID 40919482 · NCT04372433
  27. Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.
    Al-Sawaf O, Stumpf J, Zhang C, et al. · N Engl J Med · 2026 · Derived
    PubMed: PMID 41358601 · NCT04608318 (CLL17) · Leukemia, B-Cell

2025 (63 papers)

  1. Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403.
    Portell CA, Jegede OA, Wagner-Johnston N, et al. · Blood Cancer J · 2025 · Trial result
    PubMed: PMID 40355425 · NCT03113422 (PrE0403) · Lymphoma, Non-Hodgkin
  2. Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study.
    Mantzaris I, Goldfinger M, Uriel M, et al. · Blood · 2025 · Trial result
    PubMed: PMID 39919267 · NCT05342584 (Venetoclax AML) · Leukemia, Myeloid, Acute
  3. A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.
    Davids MS, Brander DM, Alvarado-Valero Y, et al. · Blood Adv · 2025 · Trial result
    PubMed: PMID 39705540 · NCT03547115 · Leukemia, Myeloid, Acute
  4. The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia.
    Alvarado-Valero Y, Cook RJ, Dinner SN, et al. · Blood Neoplasia · 2025 · Trial result
    PubMed: PMID 40809193 · NCT03547115 · Leukemia, Myeloid, Acute
  5. Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.
    Zeidner JF, Sallman DA, Récher C, et al. · Blood · 2025 · Derived
    PubMed: PMID 40009500 · NCT04778397 (ENHANCE-2) · Leukemia, Myeloid, Acute
  6. Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.
    Zeidner JF, Lin TL, Welkie RL, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 40504618 · NCT03013998
  7. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
    Wang M, Jurczak W, Trneny M, et al. · Lancet Oncol · 2025 · Derived
    PubMed: PMID 39914418 · NCT03112174 (SYMPATICO) · Lymphoma, Non-Hodgkin
  8. Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study.
    Visco C, Tabanelli V, Sacchi MV, et al. · Lancet Haematol · 2025 · Derived
    PubMed: PMID 40975105 · NCT03567876 · Lymphoma, Mantle-Cell
  9. Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.
    Venditti A, Hou JZ, Fenaux P, et al. · Leukemia · 2025 · Derived
    PubMed: PMID 40913104 · NCT02993523 (Viale-a) · Leukemia, Myeloid, Acute
  10. Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications.
    Tost J, Ak-Aksoy S, Campa D, et al. · Semin Cancer Biol · 2025 · Derived
    PubMed: PMID 39863139 · NCT03878524 · Leukemia, Myeloid, Acute
  11. Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia.
    Sonowal H, Rice WG, Bejar R, et al. · Cancer Res Commun · 2025 · Derived
    PubMed: PMID 39665627 · NCT03850574 (TUSCANY) · Leukemia, Myeloid, Acute
  12. Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia.
    Short NJ, Wierzbowska A, Cluzeau T, et al. · Leuk Lymphoma · 2025 · Derived
    PubMed: PMID 39606906 · NCT04266795 (PEVENAZA) · Leukemia, Myeloid, Acute
  13. Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma.
    Sharp J, Shana'ah AY, Voorhees TJ, et al. · J Natl Compr Canc Netw · 2025 · Derived
    PubMed: PMID 40550489 · NCT06510309 · Lymphoma
  14. Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.
    Shah NN, Zinzani PL, Wang M, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 40845254 · NCT03740529 · Leukemia, Lymphocytic, Chronic, B-Cell
  15. Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.
    Shadman M, Munir T, Robak T, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39647999 · NCT03336333 (SEQUOIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  16. Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results.
    Shadman M, Munir T, Ma S, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 40448577 · NCT03336333 (SEQUOIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  17. Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial.
    Richard-Carpentier G, Gupta G, Koraksic C, et al. · Lancet Haematol · 2025 · Derived
    PubMed: PMID 41075807 · NCT04092179 · Leukemia, Myeloid, Acute
  18. V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML.
    Pullarkat VA, Levis M, McCloskey J, et al. · Blood Neoplasia · 2025 · Derived
    PubMed: PMID 40932876 · NCT04075747 (V-FAST) · Leukemia, Myeloid, Acute
  19. Venetoclax Combined With Chemotherapy in Pediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Place AE, Karol SE, Forlenza CJ, et al. · Pediatr Blood Cancer · 2025 · Derived
    PubMed: PMID 40062648 · NCT03236857 · Leukemia, Myeloid, Acute
  20. Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer.
    Perimbeti S, Jamroze A, Gopalakrishnan D, et al. · Cancer Chemother Pharmacol · 2025 · Derived
    PubMed: PMID 41315064 · NCT03751436 · Prostatic Neoplasms
  21. Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.
    Niemann CU, Dubois J, Nasserinejad K, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 40249856 · NCT03226301
  22. Immune Dysfunction and Consequences in Chronic Lymphocytic Leukemia.
    Narkhede M, Ujjani CS · J Natl Compr Canc Netw · 2025 · Derived
    PubMed: PMID 40073834 · NCT03868722
  23. Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Munir T, Martinez-Calle N, Xu S, et al. · Oncol Ther · 2025 · Derived
    PubMed: PMID 40944848 · NCT02242942 · Leukemia, Lymphocytic, Chronic, B-Cell
  24. Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML.
    Marconi G, Piciocchi A, Audisio E, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 40048742 · NCT03455504 (V-FIRST) · Leukemia, Myeloid, Acute
  25. Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia.
    Mannis GN, Abboud CN, Daver NG, et al. · EJHaem · 2025 · Derived
    PubMed: PMID 40364806 · NCT04778410
  26. Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia.
    Luskin MR, Shimony S, Keating J, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 39546748 · NCT03319901 · Leukemia
  27. Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML.
    Lu J, Xue SL, Wang Y, et al. · Blood · 2025 · Derived
    PubMed: PMID 40009498 · NCT05177731 · Leukemia, Myeloid, Acute
  28. AL Amyloidosis: Current Treatment and Outcomes.
    Locke M, Nieto M · Adv Hematol · 2025 · Derived
    PubMed: PMID 40226119 · NCT05451771 · Immunoglobulin Light-chain Amyloidosis
  29. A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed or refractory acute myeloid leukemia.
    Liu Y, Bollino DR, Bah OM, et al. · Blood · 2025 · Derived
    PubMed: PMID 39437546 · NCT04666649 · Leukemia, Myeloid, Acute
  30. Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia.
    Liu Q, Yang J, Lv L, et al. · Front Immunol · 2025 · Derived
    PubMed: PMID 40079007 · NCT05659992 · Leukemia, Myeloid, Acute
  31. Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy.
    Lamanna N, Tam CS, Woyach JA, et al. · EJHaem · 2025 · Derived
    PubMed: PMID 39415923 · NCT03740529 · Leukemia, Lymphocytic, Chronic, B-Cell
  32. Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial.
    Kytölä S, Vänttinen I, Ruokoranta T, et al. · Blood · 2025 · Derived
    PubMed: PMID 39357056 · NCT04267081 (VenEx) · Leukemia, Myeloid, Acute
  33. Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study.
    Kumar SK, Harrison SJ, Cavo M, et al. · Lancet Haematol · 2025 · Derived
    PubMed: PMID 40587991 · NCT02755597 (Bellini) · Multiple Myeloma
  34. Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation.
    Kumar A, Soumerai J, Abramson JS, et al. · Blood · 2025 · Derived
    PubMed: PMID 39437708 · NCT03824483 · Leukemia, Lymphocytic, Chronic, B-Cell
  35. Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial.
    Kontro M, Stein AS, Pyörälä M, et al. · Lancet Haematol · 2025 · Derived
    PubMed: PMID 40449509 · NCT05428969 (BEXMAB) · Leukemia, Myeloid, Acute
  36. Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial.
    Kater AP, Kersting S, Dubois JM, et al. · Lancet Haematol · 2025 · Derived
    PubMed: PMID 41338862 · NCT04639362
  37. The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.
    Kater AP, Harrup R, Kipps TJ, et al. · Blood · 2025 · Derived
    PubMed: PMID 40009494 · NCT02005471 (MURANO) · Leukemia, Lymphocytic, Chronic, B-Cell
  38. Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia.
    Karol SE, Khaw SL, Zwaan CM, et al. · Pediatr Blood Cancer · 2025 · Derived
    PubMed: PMID 40266036 · NCT03236857 · Leukemia, Myeloid, Acute
  39. A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia.
    Kadia TM, Jen WY, Bataller A, et al. · Am J Hematol · 2025 · Derived
    PubMed: PMID 40401707 · NCT03629171 · Leukemia, Myeloid, Acute
  40. REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission.
    Jamy O, Cicic D · Future Oncol · 2025 · Derived
    PubMed: PMID 39606837 · NCT04229979 (REGAL) · Leukemia, Myeloid, Acute
  41. Intermediate-Dose Cytarabine as Postinduction AML Therapy.
    Hunault M, Pautas C, Bertoli S, et al. · NEJM Evid · 2025 · Derived
    PubMed: PMID 40552969 · NCT02416388 (BIG-1) · Leukemia, Myeloid, Acute
  42. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.
    Greenberg PL, Stone RM, Abaza Y, et al. · J Natl Compr Canc Netw · 2025 · Derived
    PubMed: PMID 40073835 · NCT03471260 · Leukemia, Myeloid, Acute
  43. Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial.
    Goulart H, Kantarjian H, Borthakur G, et al. · Cancer · 2025 · Derived
    PubMed: PMID 40193193 · NCT02115295 · Leukemia, Myeloid, Acute
  44. A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia.
    Goulart H, Jabbour E, Short NJ, et al. · Clin Lymphoma Myeloma Leuk · 2025 · Derived
    PubMed: PMID 40500616 · NCT02115295 · Leukemia, Myeloid, Acute
  45. Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial.
    Gong X, Liu W, Liu Y, et al. · Leukemia · 2025 · Derived
    PubMed: PMID 40588568 · NCT05594784
  46. Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes.
    Garcia JS, Platzbecker U, Odenike O, et al. · Blood · 2025 · Derived
    PubMed: PMID 39652823 · NCT02942290 · Leukemia, Myeloid, Acute
  47. MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.
    Fürstenau M, Robrecht S, Schneider C, et al. · Blood · 2025 · Derived
    PubMed: PMID 39883943 · NCT04515238 (CLL2-BZAG) · Leukemia, B-Cell
  48. A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.
    Eisenmann ED, Swords R, Huang Y, et al. · Cancer Res Commun · 2025 · Derived
    PubMed: PMID 40557912 · NCT03013998
  49. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.
    DiNardo CD, Marvin-Peek J, Loghavi S, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 40513054 · NCT04774393 · Leukemia, Myeloid, Acute
  50. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
    DiNardo CD, Jen WY, Takahashi K, et al. · Leukemia · 2025 · Derived
    PubMed: PMID 40000842 · NCT03214562 · Leukemia, Myeloid, Acute
  51. Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1.
    DiNardo CD, Jen WY, Montalban-Bravo G, et al. · Blood Neoplasia · 2025 · Derived
    PubMed: PMID 40979071 · NCT04874194 · Leukemia, Myeloid, Acute
  52. Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
    Davids MS, Ryan CE, Lampson BL, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39645236 · NCT03580928 (AVO) · Leukemia, Lymphocytic, Chronic, B-Cell
  53. The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy.
    Daver N, Vyas P, Huls G, et al. · Blood · 2025 · Derived
    PubMed: PMID 40233321 · NCT05079230 (ENHANCE-3) · Leukemia, Myeloid, Acute
  54. Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial.
    Condoluci A, Romano I, Dietrich D, et al. · Blood · 2025 · Derived
    PubMed: PMID 40009495 · NCT03708003 · Leukemia, Lymphocytic, Chronic, B-Cell
  55. Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial.
    Cao HY, Zhang H, Zhang Y, et al. · Lancet Haematol · 2025 · Derived
    PubMed: PMID 41338863 · NCT05149378 · Recurrence
  56. Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.
    Brown JR, Seymour JF, Jurczak W, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 39976417 · NCT03836261 (AMPLIFY) · Leukemia, Lymphocytic, Chronic, B-Cell
  57. A Phase II Trial of Geriatric Assessment-Guided Selection of Treatment Intensity in Older Adults With AML.
    Bhatt VR, Wichman CS, Koll TT, et al. · Am J Hematol · 2025 · Derived
    PubMed: PMID 40298352 · NCT03226418 · Leukemia, Myeloid, Acute
  58. CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies.
    Aakko S, Ylitalo A, Kuusanmäki H, et al. · Sci Rep · 2025 · Derived
    PubMed: PMID 40369178 · NCT05428969 (BEXMAB) · Leukemia, Myeloid, Acute
  59. Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study.
    Yu G, Zhang Y, Yu S, et al. · Clin Cancer Res · 2025 · Background
    PubMed: PMID 39531539 · NCT07507825 (VHAG) · Leukemia, Myeloid, Acute
  60. Granulocyte colony-stimulating factor plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia: a multicenter phase 2 trial.
    Wang H, Wang X, Shi T, et al. · Blood Cancer J · 2025 · Background
    PubMed: PMID 41145434 · NCT07507825 (VHAG) · Leukemia, Myeloid, Acute
  61. How I treat ETP-ALL in children.
    Summers RJ, Teachey DT, Hunger SP, et al. · Blood · 2025 · Background
    PubMed: PMID 38364183 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  62. A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies.
    DiNardo CD, Fathi AT, Kishtagari A, et al. · Clin Cancer Res · 2025 · Background
    PubMed: PMID 40238563 · NCT07283094 (FHD-286) · Leukemia, Myeloid, Acute
  63. A Real-World Evaluation of Frontline Treatment for Acute Myeloid Leukemia With Azacitidine Plus Venetoclax.
    Brandwein J, Page D, Liew E, et al. · Clin Lymphoma Myeloma Leuk · 2025 · Background
    PubMed: PMID 40023757 · NCT07283094 (FHD-286) · Leukemia, Myeloid, Acute

2024 (64 papers)

  1. Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.
    Wolff D, Cutler C, Lee SJ, et al. · N Engl J Med · 2024 · Trial result
    PubMed: PMID 39292927 · NCT07511062 · Leukemia, Myeloid, Acute
  2. Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.
    Wang ES, Goldberg AD, Tallman M, et al. · J Clin Oncol · 2024 · Trial result
    PubMed: PMID 38324741 · NCT06561880 (FLT3AML-2024)
  3. Macrophages in Acute Myeloid Leukaemia: Significant Players in Therapy Resistance and Patient Outcomes.
    Miari KE, Guzman ML, Wheadon H, et al. · Front Cell Dev Biol · 2024 · Trial result
    PubMed: PMID 34249942 · NCT07511062 · Leukemia, Myeloid, Acute
  4. Macrophages as Potential Therapeutic Targets in Acute Myeloid Leukemia.
    Mesaros O, Onciul M, Matei E, et al. · Biomedicines · 2024 · Trial result
    PubMed: PMID 39457618 · NCT07511062 · Leukemia, Myeloid, Acute
  5. Racial disparities in hematopoietic stem cell transplant: a systematic review of the literature.
    Landry I · Stem Cell Investig · 2024 · Trial result
    PubMed: PMID 35071585 · NCT06337331 · Leukemia, Myeloid, Acute
  6. "FLipping" the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors.
    Knight TE, Edwards H, Meshinchi S, et al. · Cancers (Basel) · 2024 · Trial result
    PubMed: PMID 35884458 · NCT06561880 (FLT3AML-2024)
  7. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
    Fürstenau M, Kater AP, Robrecht S, et al. · Lancet Oncol · 2024 · Trial result
    PubMed: PMID 38821083 · NCT02950051 (GAIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  8. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial.
    Fürstenau M, Giza A, Weiss J, et al. · Blood · 2024 · Trial result
    PubMed: PMID 38620072 · NCT03787264 (CLL2-BAAG) · Leukemia, B-Cell
  9. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.
    Döhner H, Pratz KW, DiNardo CD, et al. · Blood · 2024 · Trial result
    PubMed: PMID 39133921 · NCT07511062 · Leukemia, Myeloid, Acute
  10. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.
    Wierda WG, Shah NN, Cheah CY, et al. · Lancet Haematol · 2024 · Derived
    PubMed: PMID 39033770 · NCT03740529 · Leukemia, Lymphocytic, Chronic, B-Cell
  11. Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy.
    Uy GL, Pullarkat V, Baratam P, et al. · Blood Adv · 2024 · Derived
    PubMed: PMID 39418644 · NCT04038437 · Leukemia, Myeloid, Acute
  12. FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma.
    Telaraja D, Kasamon YL, Collazo JS, et al. · Clin Cancer Res · 2024 · Derived
    PubMed: PMID 37624619 · NCT03740529 · Leukemia, Lymphocytic, Chronic, B-Cell
  13. Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial.
    Tedeschi A, Frustaci AM, Condoluci A, et al. · Lancet Oncol · 2024 · Derived
    PubMed: PMID 39270702 · NCT04082897 (MOLTO)
  14. Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia.
    Tahir SK, Calvo E, Carneiro BA, et al. · Blood · 2024 · Derived
    PubMed: PMID 36720090 · NCT03082209 · Leukemia, Myeloid, Acute
  15. Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials.
    Svanberg Teglgaard R, Marquart HV, Hartling HJ, et al. · Clin Cancer Res · 2024 · Derived
    PubMed: PMID 38393694 · NCT03868722
  16. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.
    Short NJ, Nguyen D, Jabbour E, et al. · Lancet Haematol · 2024 · Derived
    PubMed: PMID 39303729 · NCT04188405 · Leukemia, Myeloid, Acute
  17. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.
    Short NJ, Jabbour E, Jain N, et al. · Blood Adv · 2024 · Derived
    PubMed: PMID 38207208 · NCT03808610 · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  18. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
    Short NJ, Daver N, Dinardo CD, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38277619 · NCT04140487 · Leukemia, Myeloid, Acute
  19. Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial.
    Russo D, Polverelli N, Bernardi S, et al. · Lancet Haematol · 2024 · Derived
    PubMed: PMID 39312920 · NCT04476199 · Leukemia, Myeloid, Acute
  20. Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy.
    Root JL, Desai PN, Ly C, et al. · Cancer Res Commun · 2024 · Derived
    PubMed: PMID 38391202 · NCT02397720 · Leukemia, Myeloid, Acute
  21. Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial.
    Roeker LE, Woyach JA, Cheah CY, et al. · Blood · 2024 · Derived
    PubMed: PMID 38861666 · NCT03740529 · Leukemia, Lymphocytic, Chronic, B-Cell
  22. A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.
    Murthy GSG, Saliba AN, Szabo A, et al. · Haematologica · 2024 · Derived
    PubMed: PMID 38572562 · NCT04172844 (PAVE) · Leukemia, Myeloid, Acute
  23. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
    Moslehi JJ, Furman RR, Tam CS, et al. · Blood Adv · 2024 · Derived
    PubMed: PMID 38502198 · NCT03336333 (SEQUOIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  24. Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.
    Melani C, Lakhotia R, Pittaluga S, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 38899693 · NCT03223610 · Lymphoma, Non-Hodgkin
  25. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
    Manda S, Anz BM, Benton C, et al. · Hematol Oncol · 2024 · Derived
    PubMed: PMID 38711253 · NCT03941964 · Leukemia, Myeloid, Acute
  26. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies.
    Langerbeins P, Giza A, Robrecht S, et al. · Blood · 2024 · Derived
    PubMed: PMID 38620092 · NCT02242942 · Leukemia, Lymphocytic, Chronic, B-Cell
  27. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia.
    Lane AA, Garcia JS, Raulston EG, et al. · Blood Adv · 2024 · Derived
    PubMed: PMID 38052038 · NCT03113643 · Leukemia, Myeloid, Acute
  28. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.
    Kwon MC, Thuring JW, Querolle O, et al. · Blood · 2024 · Derived
    PubMed: PMID 38905635 · NCT05453903 · Leukemia, Myeloid, Acute
  29. An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL.
    Kittai AS, Allan JN, James D, et al. · Blood Adv · 2024 · Derived
    PubMed: PMID 38598745 · NCT03336333 (SEQUOIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  30. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.
    Kater AP, Owen C, Moreno C, et al. · NEJM Evid · 2024 · Derived
    PubMed: PMID 38319255 · NCT03462719 (GLOW) · Leukemia, Lymphocytic, Chronic, B-Cell
  31. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
    Kater AP, Arslan Ö, Demirkan F, et al. · Lancet Oncol · 2024 · Derived
    PubMed: PMID 38467131 · NCT02756611 (VENICE I) · Leukemia, Lymphocytic, Chronic, B-Cell
  32. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.
    Jerkeman M, Kolstad A, Hutchings M, et al. · Blood Adv · 2024 · Derived
    PubMed: PMID 38113470 · NCT03505944 (VALERIA) · Lymphoma, Non-Hodgkin
  33. Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.
    Hill BT, Ma S, Zent CS, et al. · Blood Adv · 2024 · Derived
    PubMed: PMID 37871300 · NCT03379051 · Leukemia, Lymphocytic, Chronic, B-Cell
  34. A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.
    Goldfinger M, Mantzaris I, Shastri A, et al. · Blood · 2024 · Derived
    PubMed: PMID 39316768 · NCT05184842 · Leukemia, Myeloid, Acute
  35. Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab.
    Ghia P, Barnes G, Yang K, et al. · Curr Med Res Opin · 2024 · Derived
    PubMed: PMID 37752878 · NCT03336333 (SEQUOIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  36. Immune Dysfunction and Infection - Interaction between CLL and Treatment: A Reflection on Current Treatment Paradigms and Unmet Needs.
    Gargiulo E, Teglgaard RS, Faitová T, et al. · Acta Haematol · 2024 · Derived
    PubMed: PMID 37497921 · NCT03868722
  37. Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.
    Castillo JJ, Branagan AR, Sermer D, et al. · Blood · 2024 · Derived
    PubMed: PMID 37971194 · NCT04273139 · Waldenstrom Macroglobulinemia
  38. Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study.
    Biesdorf C, Guan X, Siddani SR, et al. · Cancer Chemother Pharmacol · 2024 · Derived
    PubMed: PMID 38036720 · NCT03082209 · Leukemia, Myeloid, Acute
  39. The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells.
    Bianchi M, Reichen C, Croset A, et al. · Cancer Immunol Res · 2024 · Derived
    PubMed: PMID 38683145 · NCT05673057 · Leukemia
  40. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.
    Bazinet A, Kantarjian H, Bataller A, et al. · Lancet Haematol · 2024 · Derived
    PubMed: PMID 38548404 · NCT04062266 · Leukemia, Myeloid, Acute
  41. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
    Bazinet A, Garcia-Manero G, Short N, et al. · Lancet Haematol · 2024 · Derived
    PubMed: PMID 38452788 · NCT04746235 · Leukemia, Myeloid, Acute
  42. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
    Bataller A, Montalban-Bravo G, Bazinet A, et al. · Lancet Haematol · 2024 · Derived
    PubMed: PMID 38316133 · NCT04655755 · Myelodysplastic Syndromes
  43. Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients.
    Badawi MA, Engelhardt B, Dobkowska E, et al. · Invest New Drugs · 2024 · Derived
    PubMed: PMID 39388024 · NCT02899052 · Recurrence
  44. Dosing of Venetoclax in Pediatric Patients with Relapsed Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships.
    Badawi M, Gopalakrishnan S, Engelhardt B, et al. · Clin Ther · 2024 · Derived
    PubMed: PMID 39368878 · NCT05183035 · Leukemia, Myeloid, Acute
  45. Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety.
    Badawi M, Coppola S, Eckert D, et al. · Hematol Oncol · 2024 · Derived
    PubMed: PMID 37740931 · NCT01794520 · Multiple Myeloma
  46. Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies.
    Alfaifi A, Bahashwan S, Alsaadi M, et al. · Adv Hematol · 2024 · Derived
    PubMed: PMID 39563886 · NCT03836261 (AMPLIFY) · Leukemia, Lymphocytic, Chronic, B-Cell
  47. Venetoclax Clinical Pharmacokinetics After Administration of Crushed, Ground or Whole Tablets.
    Alaei S, Wang Y, Liu Y, et al. · Clin Ther · 2024 · Derived
    PubMed: PMID 38782609 · NCT05909553
  48. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.
    Al-Sawaf O, Robrecht S, Zhang C, et al. · Blood · 2024 · Derived
    PubMed: PMID 39082668 · NCT02242942 · Leukemia, Lymphocytic, Chronic, B-Cell
  49. Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia.
    Yin Z, Yao Z, Chen D, et al. · J Cancer Res Clin Oncol · 2024 · Background
    PubMed: PMID 38969948 · NCT07507825 (VHAG) · Leukemia, Myeloid, Acute
  50. Homoharringtonine sensitized resistant acute myeloid leukemia cells to venetoclax-induced apoptosis.
    Yin Z, Gao Y, Bu X, et al. · Leuk Lymphoma · 2024 · Background
    PubMed: PMID 39235111 · NCT07507825 (VHAG) · Leukemia, Myeloid, Acute
  51. A new chemotherapy-free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study.
    Tang H, Jia W, Jia S, et al. · Am J Hematol · 2024 · Background
    PubMed: PMID 38482543 · NCT06754267 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  52. Homoharringtonine inhibits the NOTCH/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia.
    Suo S, Zhao D, Li F, et al. · Blood · 2024 · Background
    PubMed: PMID 38968151 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  53. NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients.
    Simonin M, Vasseur L, Lengliné E, et al. · Blood · 2024 · Background
    PubMed: PMID 38848537 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  54. Cell-Free DNA 5-Hydroxymethylcytosine Signatures for Lung Cancer Prognosis.
    Shao J, Olsen RJ, Kasparian S, et al. · Cells · 2024 · Background
    PubMed: PMID 38391911 · NCT07060001 · Leukemia, Myeloid, Acute
  55. Spotlight Therapeutics: making CRISPR deliver in vivo.
    Seydel C · Nat Biotechnol · 2024 · Background
    PubMed: PMID 34262172 · NCT07320235 (IMAGINE) · Leukemia, Myeloid, Acute
  56. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
    Pratz KW, Jonas BA, Pullarkat V, et al. · Am J Hematol · 2024 · Background
    PubMed: PMID 38343151 · NCT07283094 (FHD-286) · Leukemia, Myeloid, Acute
  57. The genomic basis of childhood T-lineage acute lymphoblastic leukaemia.
    Pölönen P, Di Giacomo D, Seffernick AE, et al. · Nature · 2024 · Background
    PubMed: PMID 39143224 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  58. Reduced-dose chemotherapy followed by blinatumomab in induction therapy for newly diagnosed B-cell acute lymphoblastic leukemia.
    Lu J, Zhou H, Zhou X, et al. · Cancer Med · 2024 · Background
    PubMed: PMID 38491815 · NCT06554626 · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  59. Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China.
    Leung KT, Cai J, Liu Y, et al. · Leukemia · 2024 · Background
    PubMed: PMID 38001171 · NCT06764238 (CCCG-I/HR-ALL) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  60. Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML.
    Garcia JS, Kim HT, Murdock HM, et al. · Blood Adv · 2024 · Background
    PubMed: PMID 38197938 · NCT03613532 · Leukemia, Myeloid, Acute
  61. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor.
    Fiskus W, Piel J, Collins M, et al. · Blood · 2024 · Background
    PubMed: PMID 38437498 · NCT07283094 (FHD-286) · Leukemia, Myeloid, Acute
  62. Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
    DiNardo CD, Roboz GJ, Watts JM, et al. · Blood Adv · 2024 · Background
    PubMed: PMID 38640348 · NCT07283094 (FHD-286) · Leukemia, Myeloid, Acute
  63. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
    Cai SF, Huang Y, Lance JR, et al. · Blood Adv · 2024 · Background
    PubMed: PMID 37871309 · NCT03013998
  64. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
    Abaza Y, Winer ES, Murthy GSG, et al. · Am J Hematol · 2024 · Background
    PubMed: PMID 38342997 · NCT07283094 (FHD-286) · Leukemia, Myeloid, Acute

2023 (56 papers)

  1. TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation.
    Zhao D, Zarif M, Zhou Q, et al. · Cancers (Basel) · 2023 · Trial result
    PubMed: PMID 37370821 · NCT07511062 · Leukemia, Myeloid, Acute
  2. Venetoclax plus '2 + 5' modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single-centre retrospective analysis.
    Wang H, Yao Y, Mao L, et al. · Br J Haematol · 2023 · Trial result
    PubMed: PMID 36863709 · NCT06571825 · Leukemia, Myeloid, Acute
  3. Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study.
    Kitko CL, Arora M, DeFilipp Z, et al. · J Clin Oncol · 2023 · Trial result
    PubMed: PMID 36459673 · NCT07511062 · Leukemia, Myeloid, Acute
  4. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
    Eichhorst B, Niemann CU, Kater AP, et al. · N Engl J Med · 2023 · Trial result
    PubMed: PMID 37163621 · NCT02950051 (GAIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  5. Department of Error.
    Lancet · 2023 · Trial result
    PubMed: PMID 37838437 · NCT06561880 (FLT3AML-2024)
  6. Improved access to HCT with reduced racial disparities through integration with leukemia care and haploidentical donors.
    Bashey A, Zhang X, Morris LE, et al. · Blood Adv · 2023 · Trial result
    PubMed: PMID 36961350 · NCT06337331 · Leukemia, Myeloid, Acute
  7. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
    Zeidan AM, Borate U, Pollyea DA, et al. · Am J Hematol · 2023 · Derived
    PubMed: PMID 36309981 · NCT02966782 · Myelodysplastic Syndromes
  8. A PKPD Case Study: Achieving Clinically Relevant Exposures of AZD5991 in Oncology Mouse Models.
    White MJ, Cheatham L, Wen S, et al. · AAPS J · 2023 · Derived
    PubMed: PMID 37380821 · NCT03218683 · Leukemia, Myeloid, Acute
  9. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
    Wang ML, Jurczak W, Zinzani PL, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 37192437 · NCT03740529 · Leukemia, Lymphocytic, Chronic, B-Cell
  10. Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax.
    Waclawiczek A, Leppä AM, Renders S, et al. · Cancer Discov · 2023 · Derived
    PubMed: PMID 36892565 · NCT04801797 · Leukemia, Myeloid, Acute
  11. Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication.
    Tiong IS, Loo S · Int J Mol Sci · 2023 · Derived
    PubMed: PMID 36902217 · NCT05564390 · Leukemia, Myeloid, Acute
  12. Is there a path forward for immunotherapy in patients with myelodysplastic syndromes?
    Stahl M, DeZern AE · Lancet Haematol · 2023 · Derived
    PubMed: PMID 38065202 · NCT04401748 (Verona) · Myelodysplastic Syndromes
  13. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
    Siddiqi T, Maloney DG, Kenderian SS, et al. · Lancet · 2023 · Derived
    PubMed: PMID 37295445 · NCT03331198 · Leukemia, Lymphocytic, Chronic, B-Cell
  14. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
    Short NJ, Muftuoglu M, Ong F, et al. · J Hematol Oncol · 2023 · Derived
    PubMed: PMID 37422688 · NCT03862157 · Leukemia, Myeloid, Acute
  15. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
    Senapati J, Muftuoglu M, Ishizawa J, et al. · Blood Cancer J · 2023 · Derived
    PubMed: PMID 37386016 · NCT03634228 · Leukemia, Myeloid, Acute
  16. A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.
    Sartor C, Brunetti L, Audisio E, et al. · Br J Haematol · 2023 · Derived
    PubMed: PMID 37226312 · NCT04867928 · Leukemia, Myeloid, Acute
  17. Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma.
    Phillips TJ, Bond D, Takiar R, et al. · Blood Adv · 2023 · Derived
    PubMed: PMID 37013954 · NCT03523975 · Lymphoma, Mantle-Cell
  18. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study.
    Pabst T, Papayannidis C, Demirkan F, et al. · Lancet Haematol · 2023 · Derived
    PubMed: PMID 37914483 · NCT04150887 (ELEVATE) · Leukemia, Myeloid, Acute
  19. A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1.
    Numata M, Haginoya N, Shiroishi M, et al. · Cancer Cell Int · 2023 · Derived
    PubMed: PMID 36841758 · NCT04752163 · Leukemia, Myeloid, Acute
  20. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
    Niemann CU, Munir T, Moreno C, et al. · Lancet Oncol · 2023 · Derived
    PubMed: PMID 37944541 · NCT03462719 (GLOW) · Leukemia, Lymphocytic, Chronic, B-Cell
  21. Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study.
    Moreno C, Solman IG, Tam CS, et al. · Blood Adv · 2023 · Derived
    PubMed: PMID 37315225 · NCT02910583 (Captivate) · Leukemia, Lymphocytic, Chronic, B-Cell
  22. High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
    Mauro FR, Starza ID, Messina M, et al. · Haematologica · 2023 · Derived
    PubMed: PMID 36632738 · NCT03455517 (VeRitAs) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  23. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
    Mato AR, Woyach JA, Brown JR, et al. · N Engl J Med · 2023 · Derived
    PubMed: PMID 37407001 · NCT03740529 · Leukemia, Lymphocytic, Chronic, B-Cell
  24. TP53 in AML and MDS: The new (old) kid on the block.
    Marks JA, Wang X, Fenu EM, et al. · Blood Rev · 2023 · Derived
    PubMed: PMID 36841672 · NCT04755244 · Leukemia, Myeloid, Acute
  25. Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.
    Kuusanmäki H, Kytölä S, Vänttinen I, et al. · Haematologica · 2023 · Derived
    PubMed: PMID 36519325 · NCT04267081 (VenEx) · Leukemia, Myeloid, Acute
  26. Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results.
    Gener-Ricos G, Haddad FG, Sasaki K, et al. · Clin Lymphoma Myeloma Leuk · 2023 · Derived
    PubMed: PMID 37308342 · NCT02689440 · Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  27. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.
    Garcia-Manero G, Goldberg AD, Winer ES, et al. · Lancet Haematol · 2023 · Derived
    PubMed: PMID 36990622 · NCT04214860
  28. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
    Fürstenau M, Thus YJ, Robrecht S, et al. · Blood · 2023 · Derived
    PubMed: PMID 37172204 · NCT02950051 (GAIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  29. Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription.
    Frigault MM, Mithal A, Wong H, et al. · Cancer Res Commun · 2023 · Derived
    PubMed: PMID 37882668 · NCT05371054 · Lymphoma, Non-Hodgkin
  30. Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models.
    Dewulf J, Flieswasser T, Delahaye T, et al. · EJNMMI Radiopharm Chem · 2023 · Derived
    PubMed: PMID 37093350 · NCT04150887 (ELEVATE) · Leukemia, Myeloid, Acute
  31. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.
    Daver NG, Vyas P, Kambhampati S, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 37703506 · NCT05079230 (ENHANCE-3) · Leukemia, Myeloid, Acute
  32. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
    Daver NG, Dail M, Garcia JS, et al. · Blood · 2023 · Derived
    PubMed: PMID 36265087 · NCT02670044 · Leukemia, Myeloid, Acute
  33. Reply to S. Sarosiek et al.
    Buske C, Dimopoulos MA, Morel P, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 37348018 · NCT05099471 (VIWA-1) · Neoplasms
  34. Longitudinal changes in cognitive and physical function and health-related quality of life in older adults with acute myeloid leukemia.
    Bhatt VR, Wichman C, Koll TT, et al. · J Geriatr Oncol · 2023 · Derived
    PubMed: PMID 38000343 · NCT03226418 · Leukemia, Myeloid, Acute
  35. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
    Al-Sawaf O, Zhang C, Jin HY, et al. · Nat Commun · 2023 · Derived
    PubMed: PMID 37072421 · NCT02242942 · Leukemia, Lymphocytic, Chronic, B-Cell
  36. Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms.
    Zheng X, Gao H, Lu N, et al. · Ann Hematol · 2023 · Background
    PubMed: PMID 37878011 · NCT07052422
  37. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
    Zeidan AM, Platzbecker U, Bewersdorf JP, et al. · Blood · 2023 · Background
    PubMed: PMID 36724453 · NCT07320235 (IMAGINE) · Leukemia, Myeloid, Acute
  38. Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia.
    Yoshimura S, Panetta JC, Hu J, et al. · Leukemia · 2023 · Background
    PubMed: PMID 37076694 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  39. The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial.
    Xuan L, Dai M, Jiang E, et al. · Lancet Haematol · 2023 · Background
    PubMed: PMID 36702138 · NCT07052422
  40. Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study.
    Wood BL, Devidas M, Summers RJ, et al. · Blood · 2023 · Background
    PubMed: PMID 37556734 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  41. MRD in AML: The Role of New Techniques.
    Voso MT, Ottone T, Lavorgna S, et al. · Front Oncol · 2023 · Background
    PubMed: PMID 31396481 · NCT07060001 · Leukemia, Myeloid, Acute
  42. Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia.
    Vonk CM, Al Hinai ASA, Hanekamp D, et al. · Cancers (Basel) · 2023 · Background
    PubMed: PMID 34771594 · NCT07060001 · Leukemia, Myeloid, Acute
  43. Classification of Acute Myeloid Leukemia by Cell-Free DNA 5-Hydroxymethylcytosine.
    Shao J, Shah S, Ganguly S, et al. · Genes (Basel) · 2023 · Background
    PubMed: PMID 37372359 · NCT07060001 · Leukemia, Myeloid, Acute
  44. Cell-free DNA 5-hydroxymethylcytosine is highly sensitive for MRD assessment in acute myeloid leukemia.
    Shao J, Shah S, Ganguly S, et al. · Clin Epigenetics · 2023 · Background
    PubMed: PMID 37620919 · NCT07060001 · Leukemia, Myeloid, Acute
  45. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia.
    Saygin C, Giordano G, Shimamoto K, et al. · Clin Cancer Res · 2023 · Background
    PubMed: PMID 37363966 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  46. Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
    Saliba AN, Kaufmann SH, Stein EM, et al. · Blood Adv · 2023 · Background
    PubMed: PMID 36315007 · NCT03013998
  47. Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials.
    Raetz EA, Rebora P, Conter V, et al. · J Clin Oncol · 2023 · Background
    PubMed: PMID 37487146 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  48. Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial.
    Ling Y, Xuan L, Xu N, et al. · J Clin Oncol · 2023 · Background
    PubMed: PMID 37335960 · NCT07052422
  49. Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy.
    Liang G, Wang L, You Q, et al. · Adv Sci (Weinh) · 2023 · Background
    PubMed: PMID 37271891 · NCT07060001 · Leukemia, Myeloid, Acute
  50. Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response.
    Lee SHR, Yang W, Gocho Y, et al. · Nat Med · 2023 · Background
    PubMed: PMID 36604538 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  51. Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial.
    Jin H, Zhang Y, Yu S, et al. · J Hematol Oncol · 2023 · Background
    PubMed: PMID 37120593 · NCT06483906 · Leukemia, Myeloid, Acute
  52. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.
    Jabbour E, Short NJ, Senapati J, et al. · Lancet Haematol · 2023 · Background
    PubMed: PMID 37187201 · NCT06554626 · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  53. Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
    Duong VH, Ruppert AS, Mims AS, et al. · Cancer · 2023 · Background
    PubMed: PMID 37078412 · NCT03013998
  54. Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial.
    Campbell M, Kiss C, Zimmermann M, et al. · J Clin Oncol · 2023 · Background
    PubMed: PMID 37141547 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  55. Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
    Borate U, Yang F, Press R, et al. · Blood Adv · 2023 · Background
    PubMed: PMID 37459200 · NCT03013998
  56. Short-course Venetoclax With Standard Chemotherapy Is Effective in Early T-cell Precursor Acute Lymphoblastic Leukemia.
    Borah P, Dayal N, Pathak S, et al. · J Pediatr Hematol Oncol · 2023 · Background
    PubMed: PMID 37027330 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma

2022 (77 papers)

  1. Inflammatory level under different p53 mutation status and the regulation role of curcumin in tumor microenvironment.
    Xu L, Xie X, Li X, et al. · Immunobiology · 2022 · Trial result
    PubMed: PMID 35030341 · NCT07511062 · Leukemia, Myeloid, Acute
  2. ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells.
    Valdez BC, Murray D, Yuan B, et al. · Oncotarget · 2022 · Trial result
    PubMed: PMID 35154579 · NCT06337331 · Leukemia, Myeloid, Acute
  3. Monocytic Myeloid-Derived Suppressor Cells But Not Monocytes Predict Poor Prognosis of Acute Myeloid Leukemia.
    Ren X, Tao Q, Wang H, et al. · Turk J Haematol · 2022 · Trial result
    PubMed: PMID 35965420 · NCT07511062 · Leukemia, Myeloid, Acute
  4. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
    Pullarkat VA, Lacayo NJ, Jabbour E, et al. · Cancer Discov · 2022 · Trial result
    PubMed: PMID 33593877 · NCT05054465 (ITALLI001) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  5. Peripheral levels of monocytic myeloid-derived suppressive cells before and after first induction predict relapse and survivals in AML patients.
    Peterlin P, Debord C, Eveillard M, et al. · J Cell Mol Med · 2022 · Trial result
    PubMed: PMID 36226545 · NCT07511062 · Leukemia, Myeloid, Acute
  6. Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia.
    Loke J, Labopin M, Craddock C, et al. · Cancer · 2022 · Trial result
    PubMed: PMID 35612815 · NCT06337331 · Leukemia, Myeloid, Acute
  7. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
    Kim K, Maiti A, Loghavi S, et al. · Cancer · 2022 · Trial result
    PubMed: PMID 34255353 · NCT07511062 · Leukemia, Myeloid, Acute
  8. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
    Kadia TM, Reville PK, Wang X, et al. · J Clin Oncol · 2022 · Trial result
    PubMed: PMID 35704787 · NCT06571825 · Leukemia, Myeloid, Acute
  9. Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling.
    Gu L, Surolia R, Larson-Casey JL, et al. · Cell Death Differ · 2022 · Trial result
    PubMed: PMID 34413485 · NCT05976217 · Idiopathic Pulmonary Fibrosis
  10. Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active.
    Garcia JS, Kim HT, Murdock HM, et al. · Blood Adv · 2022 · Trial result
    PubMed: PMID 34614506 · NCT06337331 · Leukemia, Myeloid, Acute
  11. Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.
    Fürstenau M, Weiss J, Giza A, et al. · Clin Cancer Res · 2022 · Trial result
    PubMed: PMID 35594173 · NCT03787264 (CLL2-BAAG) · Leukemia, B-Cell
  12. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
    Cramer P, Fürstenau M, Robrecht S, et al. · Lancet Haematol · 2022 · Trial result
    PubMed: PMID 35988545 · NCT03787264 (CLL2-BAAG) · Leukemia, B-Cell
  13. TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis.
    Brauneck F, Fischer B, Witt M, et al. · J Immunother Cancer · 2022 · Trial result
    PubMed: PMID 36549780 · NCT07511062 · Leukemia, Myeloid, Acute
  14. Structural racism is a mediator of disparities in acute myeloid leukemia outcomes.
    Abraham IE, Rauscher GH, Patel AA, et al. · Blood · 2022 · Trial result
    PubMed: PMID 35061876 · NCT06337331 · Leukemia, Myeloid, Acute
  15. Whom should we treat with novel agents? Specific indications for specific and challenging populations.
    Wilde L, Kasner M · Hematology Am Soc Hematol Educ Program · 2022 · Derived
    PubMed: PMID 34889407 · NCT03471260 · Leukemia, Myeloid, Acute
  16. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).
    Wei AH, Panayiotidis P, Montesinos P, et al. · Blood Cancer J · 2022 · Derived
    PubMed: PMID 34599139 · NCT03069352 · Leukemia, Myeloid, Acute
  17. Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation.
    Wang SY, Thomassen K, Kurch L, et al. · Clin Lymphoma Myeloma Leuk · 2022 · Derived
    PubMed: PMID 33795208 · NCT03485547 · Blastic Plasmacytoid Dendritic Cell Neoplasm
  18. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.
    Venugopal S, Maiti A, DiNardo CD, et al. · Leuk Lymphoma · 2022 · Derived
    PubMed: PMID 34474640 · NCT03404193 · Leukemia, Myeloid, Acute
  19. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications.
    Teoh J, Brown LF · Cytotherapy · 2022 · Derived
    PubMed: PMID 35610089 · NCT03331198 · Leukemia, Lymphocytic, Chronic, B-Cell
  20. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
    Tam CS, Brown JR, Kahl BS, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35810754 · NCT03336333 (SEQUOIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  21. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
    Stathis A, Mey U, Schär S, et al. · Blood Adv · 2022 · Derived
    PubMed: PMID 35537101 · NCT02877550 · Lymphoma, Non-Hodgkin
  22. Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
    Staber PB, Jurczak W, Greil R, et al. · Leuk Lymphoma · 2022 · Derived
    PubMed: PMID 34414843 · NCT02639910 (COSMOS) · Leukemia, Lymphocytic, Chronic, B-Cell
  23. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
    Soumerai JD, Mato AR, Dogan A, et al. · Lancet Haematol · 2022 · Derived
    PubMed: PMID 34826411 · NCT03824483 · Leukemia, Lymphocytic, Chronic, B-Cell
  24. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
    Siddiqi T, Soumerai JD, Dorritie KA, et al. · Blood · 2022 · Derived
    PubMed: PMID 34699592 · NCT03331198 · Leukemia, Lymphocytic, Chronic, B-Cell
  25. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.
    Short NJ, Borthakur G, Pemmaraju N, et al. · Leuk Lymphoma · 2022 · Derived
    PubMed: PMID 35442137 · NCT03390296 · Leukemia, Myeloid, Acute
  26. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
    Seymour JF, Kipps TJ, Eichhorst BF, et al. · Blood · 2022 · Derived
    PubMed: PMID 35605176 · NCT02005471 (MURANO) · Leukemia, Lymphocytic, Chronic, B-Cell
  27. Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma.
    Schjesvold F, Paiva B, Ribrag V, et al. · Clin Lymphoma Myeloma Leuk · 2022 · Derived
    PubMed: PMID 36450626 · NCT03312530 · Multiple Myeloma
  28. Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL.
    Scarfò L, Heltai S, Albi E, et al. · Blood · 2022 · Derived
    PubMed: PMID 35921541 · NCT04754035 (IMPROVE) · Leukemia, Lymphocytic, Chronic, B-Cell
  29. Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma.
    Samineni D, Huang W, Gibiansky L, et al. · Adv Ther · 2022 · Derived
    PubMed: PMID 34822104 · NCT02055820 · Lymphoma, Non-Hodgkin
  30. Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial.
    Samineni D, Gibiansky L, Wang B, et al. · Adv Ther · 2022 · Derived
    PubMed: PMID 35708885 · NCT01685892 · Leukemia, Lymphocytic, Chronic, B-Cell
  31. MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Ryan CE, Davids MS, Hermann R, et al. · Future Oncol · 2022 · Derived
    PubMed: PMID 36102212 · NCT05057494 (MAJIC) · Leukemia, Lymphocytic, Chronic, B-Cell
  32. A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer.
    Rodríguez Y, Unno K, Truica MI, et al. · Cancer Res · 2022 · Derived
    PubMed: PMID 35405009 · NCT03751436 · Prostatic Neoplasms
  33. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.
    Pratz KW, Jonas BA, Pullarkat V, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 34910556 · NCT02993523 (Viale-a) · Leukemia, Myeloid, Acute
  34. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
    Pratz KW, Chai X, Xie J, et al. · Pharmacoeconomics · 2022 · Derived
    PubMed: PMID 35696071 · NCT02993523 (Viale-a) · Leukemia, Myeloid, Acute
  35. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine.
    Pollyea DA, Pratz KW, Wei AH, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 36007102 · NCT02993523 (Viale-a) · Leukemia, Myeloid, Acute
  36. Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.
    Pollyea DA, DiNardo CD, Arellano ML, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 35046058 · NCT02993523 (Viale-a) · Leukemia, Myeloid, Acute
  37. PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer.
    Muttiah C, Whittle JR, Oakman C, et al. · Future Oncol · 2022 · Derived
    PubMed: PMID 35187951 · NCT03900884 (PALVEN)
  38. Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
    LoRusso P, Ratain MJ, Doi T, et al. · Invest New Drugs · 2022 · Derived
    PubMed: PMID 35467243 · NCT03082209 · Leukemia, Myeloid, Acute
  39. Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab.
    Lambert SL, Zhang C, Guo C, et al. · J Immunother · 2022 · Derived
    PubMed: PMID 35034046 · NCT03000257 · Neoplasms
  40. Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.
    Konopleva M, Thirman MJ, Pratz KW, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 35063965 · NCT02993523 (Viale-a) · Leukemia, Myeloid, Acute
  41. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
    Kater AP, Levin MD, Dubois J, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35654052 · NCT03226301
  42. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
    Jain N, Keating M, Thompson P, et al. · JAMA Oncol · 2022 · Derived
    PubMed: PMID 34110383 · NCT02756897 · Leukemia, Lymphocytic, Chronic, B-Cell
  43. Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia.
    Ivanov V, Yeh SP, Mayer J, et al. · Future Oncol · 2022 · Derived
    PubMed: PMID 35852098 · NCT04102020 (VIALE-M) · Leukemia, Myeloid, Acute
  44. First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
    Italiano A, Cassier PA, Lin CC, et al. · Cancer Immunol Immunother · 2022 · Derived
    PubMed: PMID 34216247 · NCT03000257 · Neoplasms
  45. A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.
    Gasparetto C, Bowles KM, Abdallah AO, et al. · Clin Lymphoma Myeloma Leuk · 2022 · Derived
    PubMed: PMID 34551886 · NCT03567616 · Recurrence
  46. Microsatellite Instability Assessment by Immunohistochemistry in Acute Myeloid Leukemia: A Reappraisal and Review of the Literature.
    El Hussein S, Daver N, Liu JL, et al. · Clin Lymphoma Myeloma Leuk · 2022 · Derived
    PubMed: PMID 34980577 · NCT02397720 · Leukemia, Myeloid, Acute
  47. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
    Davids MS, Rogers KA, Tyekucheva S, et al. · Blood · 2022 · Derived
    PubMed: PMID 34788401 · NCT03054896
  48. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
    Daver N, Perl AE, Maly J, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35849791 · NCT03625505 · Leukemia, Myeloid, Acute
  49. Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma.
    Dalton KM, Krytska K, Lochmann TL, et al. · Mol Cancer Ther · 2022 · Derived
    PubMed: PMID 34088831 · NCT03236857 · Leukemia, Myeloid, Acute
  50. Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial.
    Cochrane T, Enrico A, Gomez-Almaguer D, et al. · Leuk Lymphoma · 2022 · Derived
    PubMed: PMID 34632935 · NCT02980731 (VENICE II) · Leukemia, Lymphocytic, Chronic, B-Cell
  51. Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer.
    Calvo E, Spira A, Miguel M, et al. · Cancer Treat Res Commun · 2022 · Derived
    PubMed: PMID 34329846 · NCT03000257 · Neoplasms
  52. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
    Borthakur G, Odenike O, Aldoss I, et al. · Cancer · 2022 · Derived
    PubMed: PMID 33934351 · NCT02391480 · Leukemia, Myeloid, Acute
  53. Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia.
    Bhatt VR, Wichman C, Al-Kadhimi ZS, et al. · J Geriatr Oncol · 2022 · Derived
    PubMed: PMID 35450817 · NCT03226418 · Leukemia, Myeloid, Acute
  54. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
    Bazinet A, Darbaniyan F, Jabbour E, et al. · Lancet Haematol · 2022 · Derived
    PubMed: PMID 36063832 · NCT04160052 · Myelodysplastic Syndromes
  55. Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi.
    Ballotta L, Zinzani PL, Pileri S, et al. · Front Oncol · 2022 · Derived
    PubMed: PMID 34938664 · NCT03552692 · Immunoblastic Lymphadenopathy
  56. Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet.
    Badawi M, Chen X, Marroum P, et al. · Clin Drug Investig · 2022 · Derived
    PubMed: PMID 35829925 · NCT03069352 · Leukemia, Myeloid, Acute
  57. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.
    Aslan B, Kismali G, Iles LR, et al. · Blood Cancer J · 2022 · Derived
    PubMed: PMID 35595730 · NCT03740529 · Leukemia, Lymphocytic, Chronic, B-Cell
  58. Illness representations and psychological outcomes in chronic lymphocytic leukaemia.
    Arrato NA, Valentine TR, Byrd JC, et al. · Br J Health Psychol · 2022 · Derived
    PubMed: PMID 34608724 · NCT02296918 · Leukemia, Lymphocytic, Chronic, B-Cell
  59. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.
    Al-Sawaf O, Zhang C, Lu T, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 34709929 · NCT02242942 · Leukemia, Lymphocytic, Chronic, B-Cell
  60. Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single-arm, phase 2 trial (RJ-AML 2014).
    Zhang Y, Li X, Weng X, et al. · Am J Hematol · 2022 · Background
    PubMed: PMID 34687467 · NCT06652685 · Leukemia, Myeloid, Acute
  61. Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions.
    Zavras PD, Shastri A, Goldfinger M, et al. · Clin Cancer Res · 2022 · Background
    PubMed: PMID 34551907 · NCT07283094 (FHD-286) · Leukemia, Myeloid, Acute
  62. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
    Teachey DT, Devidas M, Wood BL, et al. · J Clin Oncol · 2022 · Background
    PubMed: PMID 35271306 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  63. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.
    Short NJ, Zhou S, Fu C, et al. · JAMA Oncol · 2022 · Background
    PubMed: PMID 33030517 · NCT07060001 · Leukemia, Myeloid, Acute
  64. The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia.
    Shi Y, Ye J, Yang Y, et al. · Front Oncol · 2022 · Background
    PubMed: PMID 34336680 · NCT06483906 · Leukemia, Myeloid, Acute
  65. Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia.
    Shao J, Wang S, West-Szymanski D, et al. · Sci Rep · 2022 · Background
    PubMed: PMID 35859008 · NCT07060001 · Leukemia, Myeloid, Acute
  66. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors.
    Sasaki K, Kantarjian HM, Short NJ, et al. · Cancer · 2022 · Background
    PubMed: PMID 33793964 · NCT06754267 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  67. Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry.
    Plesa A, Roumier C, Gutrin J, et al. · Leuk Res · 2022 · Background
    PubMed: PMID 34364023 · NCT05628623 (ERASE) · Leukemia, Myeloid, Acute
  68. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
    Moreau P, Dimopoulos MA, Mikhael J, et al. · Lancet · 2022 · Background
    PubMed: PMID 34097854 · NCT06115135 · Multiple Myeloma
  69. Efficacy and Safety of Homoharringtonine for the Treatment of Acute Myeloid Leukemia: A Meta-analysis.
    Mi R, Zhao J, Chen L, et al. · Clin Lymphoma Myeloma Leuk · 2022 · Background
    PubMed: PMID 34301487 · NCT06483906 · Leukemia, Myeloid, Acute
  70. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
    Maiti A, DiNardo CD, Qiao W, et al. · Cancer · 2022 · Background
    PubMed: PMID 34343352 · NCT05628623 (ERASE) · Leukemia, Myeloid, Acute
  71. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
    Heuser M, Freeman SD, Ossenkoppele GJ, et al. · Blood · 2022 · Background
    PubMed: PMID 34724563 · NCT07060001 · Leukemia, Myeloid, Acute
  72. Dasatinib-therapy induced sustained remission in a child with refractory TCF7-SPI1 T-cell acute lymphoblastic leukemia.
    He Y, Zhang J, Zhang Y, et al. · Pediatr Blood Cancer · 2022 · Background
    PubMed: PMID 35441457 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  73. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.
    Gocho Y, Liu J, Hu J, et al. · Nat Cancer · 2022 · Background
    PubMed: PMID 34151288 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  74. Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
    Gibson A, Trabal A, McCall D, et al. · Cancers (Basel) · 2022 · Background
    PubMed: PMID 35008312 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  75. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
    Döhner H, Wei AH, Appelbaum FR, et al. · Blood · 2022 · Background
    PubMed: PMID 35797463 · NCT07060001 · Leukemia, Myeloid, Acute
  76. 5-hydroxymethylcytosine but not MTAP methylation status can stratify malignant pleural mesothelioma based on the lineage of origin.
    Bosio M, Salvaterra E, Datturi F, et al. · Multidiscip Respir Med · 2022 · Background
    PubMed: PMID 30123503 · NCT07060001 · Leukemia, Myeloid, Acute
  77. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
    Arber DA, Orazi A, Hasserjian RP, et al. · Blood · 2022 · Background
    PubMed: PMID 35767897 · NCT07469046 · Leukemia, Myeloid, Acute

2021 (62 papers)

  1. Repolarizing heterogeneous leukemia-associated macrophages with more M1 characteristics eliminates their pro-leukemic effects.
    Yang X, Feng W, Wang R, et al. · Oncoimmunology · 2021 · Trial result
    PubMed: PMID 29632729 · NCT07511062 · Leukemia, Myeloid, Acute
  2. The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia.
    Xu ZJ, Gu Y, Wang CZ, et al. · Oncoimmunology · 2021 · Trial result
    PubMed: PMID 32002295 · NCT07511062 · Leukemia, Myeloid, Acute
  3. Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.
    Woyach JA, Blachly JS, Rogers KA, et al. · Cancer Discov · 2021 · Trial result
    PubMed: PMID 31915195 · NCT02296918 · Leukemia, Lymphocytic, Chronic, B-Cell
  4. Circulating Monocytic Myeloid-Derived Suppressor Cells Are Elevated and Associated with Poor Prognosis in Acute Myeloid Leukemia.
    Wang H, Tao Q, Wang Z, et al. · J Immunol Res · 2021 · Trial result
    PubMed: PMID 33415170 · NCT07511062 · Leukemia, Myeloid, Acute
  5. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML.
    Vadakekolathu J, Lai C, Reeder S, et al. · Blood Adv · 2021 · Trial result
    PubMed: PMID 33057635 · NCT07511062 · Leukemia, Myeloid, Acute
  6. Palmitoylated Proteins on AML-Derived Extracellular Vesicles Promote Myeloid-Derived Suppressor Cell Differentiation via TLR2/Akt/mTOR Signaling.
    Tohumeken S, Baur R, Böttcher M, et al. · Cancer Res · 2021 · Trial result
    PubMed: PMID 32605996 · NCT07511062 · Leukemia, Myeloid, Acute
  7. Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion.
    Tam CS, Robak T, Ghia P, et al. · Haematologica · 2021 · Trial result
    PubMed: PMID 33054121 · NCT03336333 (SEQUOIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  8. CSF1R Inhibition Combined with GM-CSF Reprograms Macrophages and Disrupts Protumoral Interplays with AML Cells.
    Smirnova T, Spertini C, Spertini O, et al. · Cancers (Basel) · 2021 · Trial result
    PubMed: PMID 34771453 · NCT07511062 · Leukemia, Myeloid, Acute
  9. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
    Sallman DA, McLemore AF, Aldrich AL, et al. · Blood · 2021 · Trial result
    PubMed: PMID 32730593 · NCT07511062 · Leukemia, Myeloid, Acute
  10. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.
    Maiti A, Rausch CR, Cortes JE, et al. · Haematologica · 2021 · Trial result
    PubMed: PMID 32499238 · NCT07511062 · Leukemia, Myeloid, Acute
  11. NOX4 regulates macrophage apoptosis resistance to induce fibrotic progression.
    Larson-Casey JL, Gu L, Kang J, et al. · J Biol Chem · 2021 · Trial result
    PubMed: PMID 34023385 · NCT05976217 · Idiopathic Pulmonary Fibrosis
  12. Post-translational regulation of PGC-1α modulates fibrotic repair.
    Larson-Casey JL, Gu L, Davis D, et al. · FASEB J · 2021 · Trial result
    PubMed: PMID 34038004 · NCT05976217 · Idiopathic Pulmonary Fibrosis
  13. 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis.
    Jin S, Cojocari D, Purkal JJ, et al. · Clin Cancer Res · 2021 · Trial result
    PubMed: PMID 32054729 · NCT06337331 · Leukemia, Myeloid, Acute
  14. Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.
    Chua CC, Roberts AW, Reynolds J, et al. · J Clin Oncol · 2021 · Trial result
    PubMed: PMID 32687450 · NCT06571825 · Leukemia, Myeloid, Acute
  15. The Role of Tumor-Associated Macrophages in Hematologic Malignancies.
    Cencini E, Fabbri A, Sicuranza A, et al. · Cancers (Basel) · 2021 · Trial result
    PubMed: PMID 34298810 · NCT07511062 · Leukemia, Myeloid, Acute
  16. Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses.
    Blagih J, Zani F, Chakravarty P, et al. · Cell Rep · 2021 · Trial result
    PubMed: PMID 31940491 · NCT07511062 · Leukemia, Myeloid, Acute
  17. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.
    Zinzani PL, Flinn IW, Yuen SLS, et al. · Blood · 2021 · Derived
    PubMed: PMID 32785666 · NCT02187861 · Lymphoma, Follicular
  18. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
    Wierda WG, Allan JN, Siddiqi T, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 34618601 · NCT02910583 (Captivate) · Leukemia, Lymphocytic, Chronic, B-Cell
  19. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
    Wang M, Ramchandren R, Chen R, et al. · J Hematol Oncol · 2021 · Derived
    PubMed: PMID 34717692 · NCT03112174 (SYMPATICO) · Lymphoma, Non-Hodgkin
  20. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.
    Venugopal S, Maiti A, DiNardo CD, et al. · Am J Hematol · 2021 · Derived
    PubMed: PMID 33580980 · NCT03404193 · Leukemia, Myeloid, Acute
  21. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.
    Surka C, Jin L, Mbong N, et al. · Blood · 2021 · Derived
    PubMed: PMID 33197925 · NCT04336982 · Leukemia, Myeloid, Acute
  22. Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission.
    Shallis RM, Podoltsev NA · Curr Opin Hematol · 2021 · Derived
    PubMed: PMID 33394722 · NCT03466294 · Leukemia, Myeloid, Acute
  23. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
    Rutherford SC, Abramson JS, Bartlett NL, et al. · Lancet Haematol · 2021 · Derived
    PubMed: PMID 34634256 · NCT03984448 · Lymphoma, Large B-Cell, Diffuse
  24. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
    Powderly J, Spira A, Kondo S, et al. · Clin Transl Sci · 2021 · Derived
    PubMed: PMID 32770720 · NCT03000257 · Neoplasms
  25. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
    Morschhauser F, Feugier P, Flinn IW, et al. · Blood · 2021 · Derived
    PubMed: PMID 33538797 · NCT02055820 · Lymphoma, Non-Hodgkin
  26. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
    Mato AR, Shah NN, Jurczak W, et al. · Lancet · 2021 · Derived
    PubMed: PMID 33676628 · NCT03740529 · Leukemia, Lymphocytic, Chronic, B-Cell
  27. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.
    Maiti A, DiNardo CD, Wang SA, et al. · Blood Adv · 2021 · Derived
    PubMed: PMID 33792630 · NCT03404193 · Leukemia, Myeloid, Acute
  28. Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations.
    Levin MD, Kater AP, Mattsson M, et al. · BMJ Open · 2021 · Derived
    PubMed: PMID 33060089 · NCT03226301
  29. Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients.
    Laribi K, Baugier de Materre A, Sobh M, et al. · Blood Adv · 2021 · Derived
    PubMed: PMID 33027528 · NCT03404193 · Leukemia, Myeloid, Acute
  30. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
    Kumar SK, Harrison SJ, Cavo M, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 33129376 · NCT02755597 (Bellini) · Multiple Myeloma
  31. Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia.
    Kipps TJ · Cancer J · 2021 · Derived
    PubMed: PMID 34398557 · NCT04501939 (Venetoclax) · Leukemia, Lymphocytic, Chronic, B-Cell
  32. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
    Kater AP, Wu JQ, Kipps T, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 32986498 · NCT02005471 (MURANO) · Leukemia, Lymphocytic, Chronic, B-Cell
  33. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
    Kadia TM, Reville PK, Borthakur G, et al. · Lancet Haematol · 2021 · Derived
    PubMed: PMID 34329576 · NCT02115295 · Leukemia, Myeloid, Acute
  34. The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia.
    Gordon MJ, Danilov AV · Ther Adv Hematol · 2021 · Derived
    PubMed: PMID 33796237 · NCT03836261 (AMPLIFY) · Leukemia, Lymphocytic, Chronic, B-Cell
  35. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
    Garg R, Allen KJH, Dawicki W, et al. · Cancer Med · 2021 · Derived
    PubMed: PMID 33347715 · NCT03867682 · Leukemia, Myeloid, Acute
  36. Allogeneic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes and Prevention of Relapse.
    Franke GN, Lückemeier P, Platzbecker U, et al. · Clin Lymphoma Myeloma Leuk · 2021 · Derived
    PubMed: PMID 33191169 · NCT02966782 · Myelodysplastic Syndromes
  37. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.
    Dickinson M, Briones J, Herrera AF, et al. · Blood Adv · 2021 · Derived
    PubMed: PMID 34581757 · NCT03255096 · Lymphoma, Large B-Cell, Diffuse
  38. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
    Davids MS, Lampson BL, Tyekucheva S, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 34534514 · NCT03580928 (AVO) · Leukemia, Lymphocytic, Chronic, B-Cell
  39. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Costa LJ, Davies FE, Monohan GP, et al. · Blood Adv · 2021 · Derived
    PubMed: PMID 34470049 · NCT02899052 · Recurrence
  40. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
    Bahlis NJ, Baz R, Harrison SJ, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 34388020 · NCT03314181 · Neoplasms
  41. Hydroxymethylation and tumors: can 5-hydroxymethylation be used as a marker for tumor diagnosis and treatment?
    Xu T, Gao H · Hum Genomics · 2021 · Background
    PubMed: PMID 32375881 · NCT07060001 · Leukemia, Myeloid, Acute
  42. 5-Hydroxymethylcytosine signature in circulating cell-free DNA as a potential diagnostic factor for early-stage colorectal cancer and precancerous adenoma.
    Xiao Z, Wu W, Wu C, et al. · Mol Oncol · 2021 · Background
    PubMed: PMID 33107199 · NCT07060001 · Leukemia, Myeloid, Acute
  43. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
    Wei AH, Montesinos P, Ivanov V, et al. · Blood · 2021 · Background
    PubMed: PMID 32219442 · NCT03069352 · Leukemia, Myeloid, Acute
  44. Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia.
    Shi Y, Beckett MC, Blair HJ, et al. · Haematologica · 2021 · Background
    PubMed: PMID 32139432 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  45. Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial.
    Rosenberg L, Levaux H, Levine RL, et al. · Ther Innov Regul Sci · 2021 · Background
    PubMed: PMID 33997942 · NCT03013998
  46. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
    Richard-Carpentier G, Jabbour E, Short NJ, et al. · Clin Lymphoma Myeloma Leuk · 2021 · Background
    PubMed: PMID 32035785 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  47. Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.
    Regidor B, Goldwater MS, Wang J, et al. · Ann Hematol · 2021 · Background
    PubMed: PMID 33987683 · NCT06115135 · Multiple Myeloma
  48. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
    Pollyea DA, Bixby D, Perl A, et al. · J Natl Compr Canc Netw · 2021 · Background
    PubMed: PMID 33406488 · NCT07320235 (IMAGINE) · Leukemia, Myeloid, Acute
  49. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
    Norsworthy KJ, Mulkey F, Scott EC, et al. · Clin Cancer Res · 2021 · Background
    PubMed: PMID 32393603 · NCT07283094 (FHD-286) · Leukemia, Myeloid, Acute
  50. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine.
    Morita K, Jain N, Kantarjian H, et al. · Am J Hematol · 2021 · Background
    PubMed: PMID 33639000 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  51. Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia.
    Kolitz JE, Strickland SA, Cortes JE, et al. · Leuk Lymphoma · 2021 · Background
    PubMed: PMID 31760835 · NCT05628623 (ERASE) · Leukemia, Myeloid, Acute
  52. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM, Kadia TM, DiNardo CD, et al. · Cancer · 2021 · Background
    PubMed: PMID 33734442 · NCT06483906 · Leukemia, Myeloid, Acute
  53. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Izutsu K, Yamamoto K, Kato K, et al. · Int J Hematol · 2021 · Background
    PubMed: PMID 33094474 · NCT02265731 · Leukemia, Myeloid, Acute
  54. Pediatric acute lymphoblastic leukemia.
    Inaba H, Mullighan CG · Haematologica · 2021 · Background
    PubMed: PMID 33054110 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  55. Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network.
    Gu X, Tohme R, Tomlinson B, et al. · Leukemia · 2021 · Background
    PubMed: PMID 32770088 · NCT07283094 (FHD-286) · Leukemia, Myeloid, Acute
  56. Venetoclax is safe and efficacious in relapsed/refractory AML.
    Ganzel C, Ram R, Gural A, et al. · Leuk Lymphoma · 2021 · Background
    PubMed: PMID 32420775 · NCT05628623 (ERASE) · Leukemia, Myeloid, Acute
  57. Fischer K, Al-Sawaf O, Fink A-M, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129(19):2702-2705.
    Blood · 2021 · Background
    PubMed: PMID 28705863 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell
  58. Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies.
    Feld J, Tremblay D, Dougherty M, et al. · Hemasphere · 2021 · Background
    PubMed: PMID 33718803 · NCT07320235 (IMAGINE) · Leukemia, Myeloid, Acute
  59. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.
    Dunsmore KP, Winter SS, Devidas M, et al. · J Clin Oncol · 2021 · Background
    PubMed: PMID 32813610 · NCT06742463 · Recurrence
  60. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
    DiNardo CD, Lachowiez CA, Takahashi K, et al. · J Clin Oncol · 2021 · Background
    PubMed: PMID 34043428 · NCT05628623 (ERASE) · Leukemia, Myeloid, Acute
  61. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
    Burd A, Levine RL, Ruppert AS, et al. · Nat Med · 2021 · Background
    PubMed: PMID 33106665 · NCT03013998
  62. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.
    Bewersdorf JP, Giri S, Wang R, et al. · Haematologica · 2021 · Background
    PubMed: PMID 33131256 · NCT05362942 · Leukemia, Myeloid, Acute

2020 (48 papers)

  1. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.
    Solomon SR, St Martin A, Shah NN, et al. · Blood Adv · 2020 · Trial result
    PubMed: PMID 31582392 · NCT06337331 · Leukemia, Myeloid, Acute
  2. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
    Solh MM, Solomon SR, Morris LE, et al. · Biol Blood Marrow Transplant · 2020 · Trial result
    PubMed: PMID 30244109 · NCT06337331 · Leukemia, Myeloid, Acute
  3. First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.
    Piha-Paul SA, Sachdev JC, Barve M, et al. · Clin Cancer Res · 2020 · Trial result
    PubMed: PMID 31420359 · NCT02391480 · Leukemia, Myeloid, Acute
  4. Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects.
    Mu S, Tang Z, Novotny W, et al. · Cancer Chemother Pharmacol · 2020 · Trial result
    PubMed: PMID 31875923 · NCT03336333 (SEQUOIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  5. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
    DiNardo CD, Jonas BA, Pullarkat V, et al. · N Engl J Med · 2020 · Trial result
    PubMed: PMID 32786187 · NCT06571825 · Leukemia, Myeloid, Acute
  6. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.
    Roberts AW, Ma S, Kipps TJ, et al. · Blood · 2020 · Derived
    PubMed: PMID 31023700 · NCT02141282 · Leukemia, Lymphocytic, Chronic, B-Cell
  7. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
    Naqvi K, Jabbour E, Skinner J, et al. · Cancer · 2020 · Derived
    PubMed: PMID 31553487 · NCT02689440 · Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  8. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.
    Karol SE, Alexander TB, Budhraja A, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 32171069 · NCT03194932 · Leukemia, Myeloid, Acute
  9. COVID-19 among fit patients with CLL treated with venetoclax-based combinations.
    Fürstenau M, Langerbeins P, De Silva N, et al. · Leukemia · 2020 · Derived
    PubMed: PMID 32601378 · NCT02950051 (GAIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  10. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
    Frame S, Saladino C, MacKay C, et al. · PLoS One · 2020 · Derived
    PubMed: PMID 32645016 · NCT04017546 · Leukemia, Myeloid, Acute
  11. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
    Flinn IW, Gribben JG, Dyer MJS, et al. · Blood · 2020 · Derived
    PubMed: PMID 30862645 · NCT01685892 · Leukemia, Lymphocytic, Chronic, B-Cell
  12. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD, Maiti A, Rausch CR, et al. · Lancet Haematol · 2020 · Derived
    PubMed: PMID 32896301 · NCT03404193 · Leukemia, Myeloid, Acute
  13. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
    Al-Sawaf O, Zhang C, Tandon M, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 32888452 · NCT02242942 · Leukemia, Lymphocytic, Chronic, B-Cell
  14. Acute Myeloid Leukemia: Aging and Epigenetics.
    Zjablovskaja P, Florian MC · Cancers (Basel) · 2020 · Background
    PubMed: PMID 31906064 · NCT07060001 · Leukemia, Myeloid, Acute
  15. Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications.
    Yang X, Wong MPM, Ng RK, et al. · Int J Mol Sci · 2020 · Background
    PubMed: PMID 31527484 · NCT07060001 · Leukemia, Myeloid, Acute
  16. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.
    Winters AC, Gutman JA, Purev E, et al. · Blood Adv · 2020 · Background
    PubMed: PMID 31648312 · NCT04666649 · Leukemia, Myeloid, Acute
  17. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
    Wei AH, Strickland SA, Hou JZ, et al. · J Clin Oncol · 2020 · Background
    PubMed: PMID 30892988 · NCT02287233 · Leukemia, Myeloid, Acute
  18. Epigenomic analysis of 5-hydroxymethylcytosine (5hmC) reveals novel DNA methylation markers for lung cancers.
    Wang Z, Du M, Yuan Q, et al. · Neoplasia · 2020 · Background
    PubMed: PMID 32062069 · NCT07060001 · Leukemia, Myeloid, Acute
  19. Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse.
    Ueda M, El-Jurdi N, Cooper B, et al. · Biol Blood Marrow Transplant · 2020 · Background
    PubMed: PMID 30599207 · NCT07283094 (FHD-286) · Leukemia, Myeloid, Acute
  20. 5-Hydroxymethylcytosine as a potential epigenetic biomarker in papillary thyroid carcinoma.
    Tong M, Gao S, Qi W, et al. · Oncol Lett · 2020 · Background
    PubMed: PMID 31452729 · NCT07060001 · Leukemia, Myeloid, Acute
  21. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia.
    Teachey DT, Pui CH · Lancet Oncol · 2020 · Background
    PubMed: PMID 30842058 · NCT06764238 (CCCG-I/HR-ALL) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  22. How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children.
    Teachey DT, O'Connor D · Blood · 2020 · Background
    PubMed: PMID 31738819 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  23. Differentiation syndrome in acute promyelocytic leukaemia.
    Stahl M, Tallman MS · Br J Haematol · 2020 · Background
    PubMed: PMID 31410848 · NCT07283094 (FHD-286) · Leukemia, Myeloid, Acute
  24. T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol.
    Quist-Paulsen P, Toft N, Heyman M, et al. · Leukemia · 2020 · Background
    PubMed: PMID 31611626 · NCT06742463 · Recurrence
  25. Venetoclax for AML: changing the treatment paradigm.
    Pollyea DA, Amaya M, Strati P, et al. · Blood Adv · 2020 · Background
    PubMed: PMID 31869416 · NCT05048615 · Leukemia, Myeloid, Acute
  26. Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia.
    Patzke CL, Duffy AP, Duong VH, et al. · J Clin Med · 2020 · Background
    PubMed: PMID 32079074 · NCT04666649 · Leukemia, Myeloid, Acute
  27. Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS.
    Nakamura S, Yokoyama K, Shimizu E, et al. · Blood · 2020 · Background
    PubMed: PMID 30936070 · NCT07060001 · Leukemia, Myeloid, Acute
  28. Global DNA 5-Hydroxymethylcytosine and 5-Formylcytosine Contents Are Decreased in the Early Stage of Hepatocellular Carcinoma.
    Liu J, Jiang J, Mo J, et al. · Hepatology · 2020 · Background
    PubMed: PMID 30070373 · NCT07060001 · Leukemia, Myeloid, Acute
  29. Recent drug approvals for acute myeloid leukemia.
    Lai C, Doucette K, Norsworthy K, et al. · J Hematol Oncol · 2020 · Background
    PubMed: PMID 31533852 · NCT04666649 · Leukemia, Myeloid, Acute
  30. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.
    Jonas BA, Pollyea DA · Leukemia · 2020 · Background
    PubMed: PMID 31628431 · NCT07283094 (FHD-286) · Leukemia, Myeloid, Acute
  31. Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16.
    Jeha S, Pei D, Choi J, et al. · J Clin Oncol · 2020 · Background
    PubMed: PMID 31657981 · NCT06764238 (CCCG-I/HR-ALL) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  32. Assessment of l-Asparaginase Pharmacodynamics in Mouse Models of Cancer.
    Horvath TD, Chan WK, Pontikos MA, et al. · Metabolites · 2020 · Background
    PubMed: PMID 30634463 · NCT04666649 · Leukemia, Myeloid, Acute
  33. Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA.
    Guler GD, Ning Y, Ku CJ, et al. · Nat Commun · 2020 · Background
    PubMed: PMID 33077732 · NCT07060001 · Leukemia, Myeloid, Acute
  34. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.
    Guièze R, Liu VM, Rosebrock D, et al. · Cancer Cell · 2020 · Background
    PubMed: PMID 31543463 · NCT04666649 · Leukemia, Myeloid, Acute
  35. Venetoclax-based therapies for acute myeloid leukemia.
    Guerra VA, DiNardo C, Konopleva M, et al. · Best Pract Res Clin Haematol · 2020 · Background
    PubMed: PMID 31203996 · NCT05048615 · Leukemia, Myeloid, Acute
  36. How I treat acute myeloid leukemia in the era of new drugs.
    DiNardo CD, Wei AH · Blood · 2020 · Background
    PubMed: PMID 31765470 · NCT07320235 (IMAGINE) · Leukemia, Myeloid, Acute
  37. Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia.
    Daneshbod Y, Kohan L, Taghadosi V, et al. · Curr Treat Options Oncol · 2020 · Background
    PubMed: PMID 30741367 · NCT04666649 · Leukemia, Myeloid, Acute
  38. Outpatient low toxic regimen with bortezomib in relapsed/refractory acute lymphoblastic leukemia in pediatrics and AYA patients: Single-center Mexican experience.
    Colunga-Pedraza JE, González-Llano O, González-Martinez CE, et al. · Pediatr Blood Cancer · 2020 · Background
    PubMed: PMID 32159276 · NCT07039877
  39. Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond.
    Choi JH, Bogenberger JM, Tibes R, et al. · Target Oncol · 2020 · Background
    PubMed: PMID 32319019 · NCT07507825 (VHAG) · Leukemia, Myeloid, Acute
  40. Prognostic implications of 5-hydroxymethylcytosines from circulating cell-free DNA in diffuse large B-cell lymphoma.
    Chiu BC, Zhang Z, You Q, et al. · Blood Adv · 2020 · Background
    PubMed: PMID 31570490 · NCT07060001 · Leukemia, Myeloid, Acute
  41. Prognostic value of downregulated 5-hydroxymethylcytosine expression in renal cell carcinoma: a 10 year follow-up retrospective study.
    Chen S, Zhou Q, Liu T, et al. · J Cancer · 2020 · Background
    PubMed: PMID 31956367 · NCT07060001 · Leukemia, Myeloid, Acute
  42. Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia.
    Campos EDV, Pinto R · Hematol Transfus Cell Ther · 2020 · Background
    PubMed: PMID 31084767 · NCT04666649 · Leukemia, Myeloid, Acute
  43. Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies.
    Buldini B, Maurer-Granofszky M, Varotto E, et al. · Front Pediatr · 2020 · Background
    PubMed: PMID 31681710 · NCT07060001 · Leukemia, Myeloid, Acute
  44. Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
    Bade NA, Lu C, Patzke CL, et al. · J Oncol Pharm Pract · 2020 · Background
    PubMed: PMID 30917738 · NCT04666649 · Leukemia, Myeloid, Acute
  45. Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies.
    Awada H, Mahfouz RZ, Kishtagari A, et al. · Br J Haematol · 2020 · Background
    PubMed: PMID 31736067 · NCT07283094 (FHD-286) · Leukemia, Myeloid, Acute
  46. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
    Attal M, Richardson PG, Rajkumar SV, et al. · Lancet · 2020 · Background
    PubMed: PMID 31735560 · NCT06115135 · Multiple Myeloma
  47. 5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype.
    Applebaum MA, Barr EK, Karpus J, et al. · JCO Precis Oncol · 2020 · Background
    PubMed: PMID 31179414 · NCT07060001 · Leukemia, Myeloid, Acute
  48. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
    Antar AI, Otrock ZK, Jabbour E, et al. · Leukemia · 2020 · Background
    PubMed: PMID 31919472 · NCT07320235 (IMAGINE) · Leukemia, Myeloid, Acute

2019 (40 papers)

  1. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
    Zelenetz AD, Salles G, Mason KD, et al. · Blood · 2019 · Trial result
    PubMed: PMID 30850381 · NCT02055820 · Lymphoma, Non-Hodgkin
  2. Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells.
    Valdez BC, Tang X, Li Y, et al. · Exp Hematol · 2019 · Trial result
    PubMed: PMID 30102945 · NCT06337331 · Leukemia, Myeloid, Acute
  3. Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study.
    Østgård LSG, Lund JL, Nørgaard JM, et al. · Biol Blood Marrow Transplant · 2019 · Trial result
    PubMed: PMID 29051022 · NCT06337331 · Leukemia, Myeloid, Acute
  4. CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.
    Edwards DK, Watanabe-Smith K, Rofelty A, et al. · Blood · 2019 · Trial result
    PubMed: PMID 30425048 · NCT07511062 · Leukemia, Myeloid, Acute
  5. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
    Tron AE, Belmonte MA, Adam A, et al. · Nat Commun · 2019 · Derived
    PubMed: PMID 30559424 · NCT03218683 · Leukemia, Myeloid, Acute
  6. Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.
    Place AE, Goldsmith K, Bourquin JP, et al. · Future Oncol · 2019 · Derived
    PubMed: PMID 29595064 · NCT03236857 · Leukemia, Myeloid, Acute
  7. Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
    Naqvi K, Jabbour E, Skinner J, et al. · Cancer · 2019 · Derived
    PubMed: PMID 29723397 · NCT02689440 · Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  8. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
    Morita K, Kantarjian HM, Wang F, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 29702001 · NCT02115295 · Leukemia, Myeloid, Acute
  9. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
    Kater AP, Seymour JF, Hillmen P, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 30523712 · NCT02005471 (MURANO) · Leukemia, Lymphocytic, Chronic, B-Cell
  10. Ibrutinib and Venetoclax for First-Line Treatment of CLL.
    Jain N, Keating M, Thompson P, et al. · N Engl J Med · 2019 · Derived
    PubMed: PMID 31141631 · NCT02756897 · Leukemia, Lymphocytic, Chronic, B-Cell
  11. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
    Fischer K, Al-Sawaf O, Bahlo J, et al. · N Engl J Med · 2019 · Derived
    PubMed: PMID 31166681 · NCT02242942 · Leukemia, Lymphocytic, Chronic, B-Cell
  12. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
    Coutre S, Choi M, Furman RR, et al. · Blood · 2019 · Derived
    PubMed: PMID 29305552 · NCT02141282 · Leukemia, Lymphocytic, Chronic, B-Cell
  13. Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy.
    Zeng C, Stroup EK, Zhang Z, et al. · Cancer Commun (Lond) · 2019 · Background
    PubMed: PMID 30922396 · NCT07060001 · Leukemia, Myeloid, Acute
  14. Global distribution of DNA hydroxymethylation and DNA methylation in chronic lymphocytic leukemia.
    Wernig-Zorc S, Yadav MP, Kopparapu PK, et al. · Epigenetics Chromatin · 2019 · Background
    PubMed: PMID 30616658 · NCT07060001 · Leukemia, Myeloid, Acute
  15. Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
    Tucker DW, Getchell CR, McCarthy ET, et al. · Clin Cancer Res · 2019 · Background
    PubMed: PMID 29263182 · NCT07060001 · Leukemia, Myeloid, Acute
  16. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.
    Toft N, Birgens H, Abrahamsson J, et al. · Leukemia · 2019 · Background
    PubMed: PMID 28819280 · NCT06764238 (CCCG-I/HR-ALL) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  17. Circulating tumor DNA 5-hydroxymethylcytosine as a novel diagnostic biomarker for esophageal cancer.
    Tian X, Sun B, Chen C, et al. · Cell Res · 2019 · Background
    PubMed: PMID 29467383 · NCT07060001 · Leukemia, Myeloid, Acute
  18. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.
    Stock W, Luger SM, Advani AS, et al. · Blood · 2019 · Background
    PubMed: PMID 30658992 · NCT06742463 · Recurrence
  19. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
    Soumerai JD, Ni A, Darif M, et al. · Lancet Haematol · 2019 · Background
    PubMed: PMID 31109827 · NCT04560322 · Leukemia, Lymphocytic, Chronic, B-Cell
  20. Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma.
    Rahbari KJ, Nosrati JD, Spektor TM, et al. · Clin Lymphoma Myeloma Leuk · 2019 · Background
    PubMed: PMID 30033209 · NCT06115135 · Multiple Myeloma
  21. Loss of 5-Hydroxymethylcytosine Is an Epigenetic Biomarker in Cutaneous T-Cell Lymphoma.
    Qiu L, Liu F, Yi S, et al. · J Invest Dermatol · 2019 · Background
    PubMed: PMID 29803640 · NCT07060001 · Leukemia, Myeloid, Acute
  22. A Novel l-Asparaginase with low l-Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias In Vivo.
    Nguyen HA, Su Y, Zhang JY, et al. · Cancer Res · 2019 · Background
    PubMed: PMID 29343523 · NCT04666649 · Leukemia, Myeloid, Acute
  23. Valence-band structure of alpha -Sn determined by angle-resolved photoemission.
    Middelmann HU, Sorba L, Hinkel V, et al. · Phys Rev B Condens Matter · 2019 · Background
    PubMed: PMID 9941458 · NCT06764238 (CCCG-I/HR-ALL) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  24. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.
    Mei M, Aldoss I, Marcucci G, et al. · Am J Hematol · 2019 · Background
    PubMed: PMID 30499168 · NCT05893472 · Leukemia, Myeloid, Acute
  25. Loss of 5-hydroxymethylcytosine is a frequent event in peripheral T-cell lymphomas.
    Lemonnier F, Poullot E, Dupuy A, et al. · Haematologica · 2019 · Background
    PubMed: PMID 29242297 · NCT07060001 · Leukemia, Myeloid, Acute
  26. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
    Lancet JE, Uy GL, Cortes JE, et al. · J Clin Oncol · 2019 · Background
    PubMed: PMID 30024784 · NCT07060001 · Leukemia, Myeloid, Acute
  27. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
    Hallek M, Cheson BD, Catovsky D, et al. · Blood · 2019 · Background
    PubMed: PMID 29540348 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell
  28. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
    Gökbuget N, Dombret H, Bonifacio M, et al. · Blood · 2019 · Background
    PubMed: PMID 29358182 · NCT06554626 · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  29. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
    Freeman SD, Hills RK, Virgo P, et al. · J Clin Oncol · 2019 · Background
    PubMed: PMID 29601212 · NCT05628623 (ERASE) · Leukemia, Myeloid, Acute
  30. Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia.
    Emadi A, Law JY, Strovel ET, et al. · Cancer Chemother Pharmacol · 2019 · Background
    PubMed: PMID 29119293 · NCT04666649 · Leukemia, Myeloid, Acute
  31. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
    DiNardo CD, Rausch CR, Benton C, et al. · Am J Hematol · 2019 · Background
    PubMed: PMID 29218851 · NCT04666649 · Leukemia, Myeloid, Acute
  32. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
    DiNardo CD, Pratz K, Pullarkat V, et al. · Blood · 2019 · Background
    PubMed: PMID 30361262 · NCT05048615 · Leukemia, Myeloid, Acute
  33. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
    Cramer P, von Tresckow J, Bahlo J, et al. · Lancet Oncol · 2019 · Background
    PubMed: PMID 30115596 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell
  34. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center.
    Ciurea SO, Labopin M, Socie G, et al. · Cancer · 2019 · Background
    PubMed: PMID 29469961 · NCT04666649 · Leukemia, Myeloid, Acute
  35. Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-κB repressing factor.
    Chen XJ, Zhang WN, Chen B, et al. · Proc Natl Acad Sci U S A · 2019 · Background
    PubMed: PMID 30659143 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  36. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma.
    Cai J, Chen L, Zhang Z, et al. · Gut · 2019 · Background
    PubMed: PMID 31358576 · NCT07060001 · Leukemia, Myeloid, Acute
  37. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
    Bray F, Ferlay J, Soerjomataram I, et al. · CA Cancer J Clin · 2019 · Background
    PubMed: PMID 30207593 · NCT06483906 · Leukemia, Myeloid, Acute
  38. What makes a good new therapeutic L-asparaginase?
    Beckett A, Gervais D · World J Microbiol Biotechnol · 2019 · Background
    PubMed: PMID 31552479 · NCT04666649 · Leukemia, Myeloid, Acute
  39. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
    Barr PM, Robak T, Owen C, et al. · Haematologica · 2019 · Background
    PubMed: PMID 29880603 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell
  40. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
    Aldoss I, Yang D, Aribi A, et al. · Haematologica · 2019 · Background
    PubMed: PMID 29545346 · NCT07283094 (FHD-286) · Leukemia, Myeloid, Acute

2018 (21 papers)

  1. Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia.
    Solomon SR, Sizemore CA, Zhang X, et al. · Biol Blood Marrow Transplant · 2018 · Trial result
    PubMed: PMID 27453362 · NCT06337331 · Leukemia, Myeloid, Acute
  2. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Seymour JF, Kipps TJ, Eichhorst B, et al. · N Engl J Med · 2018 · Derived
    PubMed: PMID 29562156 · NCT02005471 (MURANO) · Leukemia, Lymphocytic, Chronic, B-Cell
  3. CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial.
    Oki Y, Kelly KR, Flinn I, et al. · Haematologica · 2018 · Derived
    PubMed: PMID 28860342 · NCT01742988 · Lymphoma, Large B-Cell, Diffuse
  4. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
    Jones JA, Mato AR, Wierda WG, et al. · Lancet Oncol · 2018 · Derived
    PubMed: PMID 29246803 · NCT02141282 · Leukemia, Lymphocytic, Chronic, B-Cell
  5. 5-Hydroxymethylome in Circulating Cell-free DNA as A Potential Biomarker for Non-small-cell Lung Cancer.
    Zhang J, Han X, Gao C, et al. · Genomics Proteomics Bioinformatics · 2018 · Background
    PubMed: PMID 30010036 · NCT07060001 · Leukemia, Myeloid, Acute
  6. Ultimate Precision: Targeting Cancer but Not Normal Self-replication.
    Velcheti V, Schrump D, Saunthararajah Y, et al. · Am Soc Clin Oncol Educ Book · 2018 · Background
    PubMed: PMID 30231326 · NCT07283094 (FHD-286) · Leukemia, Myeloid, Acute
  7. Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).
    Touzeau C, Le Gouill S, Mahé B, et al. · Haematologica · 2018 · Background
    PubMed: PMID 28057737 · NCT06115135 · Multiple Myeloma
  8. Acute lymphoblastic leukemia: a comprehensive review and 2017 update.
    Terwilliger T, Abdul-Hay M · Blood Cancer J · 2018 · Background
    PubMed: PMID 28665419 · NCT06387121 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  9. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
    Tahir SK, Smith ML, Hessler P, et al. · BMC Cancer · 2018 · Background
    PubMed: PMID 28578655 · NCT04666649 · Leukemia, Myeloid, Acute
  10. Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.
    Othus M, Wood BL, Stirewalt DL, et al. · Leukemia · 2018 · Background
    PubMed: PMID 27133827 · NCT05628623 (ERASE) · Leukemia, Myeloid, Acute
  11. Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.
    Niu X, Zhao J, Ma J, et al. · Clin Cancer Res · 2018 · Background
    PubMed: PMID 27103402 · NCT05628623 (ERASE) · Leukemia, Myeloid, Acute
  12. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.
    Magina KN, Pregartner G, Zebisch A, et al. · Blood · 2018 · Background
    PubMed: PMID 28679736 · NCT05628623 (ERASE) · Leukemia, Myeloid, Acute
  13. 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers.
    Li W, Zhang X, Lu X, et al. · Cell Res · 2018 · Background
    PubMed: PMID 28925386 · NCT07060001 · Leukemia, Myeloid, Acute
  14. Acute Myeloid Leukemia: The Good, the Bad, and the Ugly.
    Kuykendall A, Duployez N, Boissel N, et al. · Am Soc Clin Oncol Educ Book · 2018 · Background
    PubMed: PMID 30231330 · NCT04666649 · Leukemia, Myeloid, Acute
  15. Cell-free DNA - Minimally invasive marker of hematological malignancies.
    Kubaczkova V, Vrabel D, Sedlarikova L, et al. · Eur J Haematol · 2018 · Background
    PubMed: PMID 28692178 · NCT07060001 · Leukemia, Myeloid, Acute
  16. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.
    Herling CD, Abedpour N, Weiss J, et al. · Nat Commun · 2018 · Background
    PubMed: PMID 29463802 · NCT03986034 · Leukemia, Lymphocytic, Chronic, B-Cell
  17. Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis.
    Geyer MB, Hsu M, Devlin SM, et al. · Blood · 2018 · Background
    PubMed: PMID 28122741 · NCT06387121 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  18. Circulating cell-free DNA in hematological malignancies.
    Buedts L, Vandenberghe P · Haematologica · 2018 · Background
    PubMed: PMID 27582567 · NCT07060001 · Leukemia, Myeloid, Acute
  19. TET2 in Normal and Malignant Hematopoiesis.
    Bowman RL, Levine RL · Cold Spring Harb Perspect Med · 2018 · Background
    PubMed: PMID 28242787 · NCT07060001 · Leukemia, Myeloid, Acute
  20. Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia.
    Bongiovanni D, Saccomani V, Piovan E, et al. · Int J Mol Sci · 2018 · Background
    PubMed: PMID 28872614 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  21. Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells.
    Bodo J, Zhao X, Durkin L, et al. · Oncotarget · 2018 · Background
    PubMed: PMID 27661108 · NCT04666649 · Leukemia, Myeloid, Acute

2017 (30 papers)

  1. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia.
    Pyzer AR, Stroopinsky D, Rajabi H, et al. · Blood · 2017 · Trial result
    PubMed: PMID 28126925 · NCT07511062 · Leukemia, Myeloid, Acute
  2. Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
    Poiré X, Labopin M, Maertens J, et al. · J Hematol Oncol · 2017 · Trial result
    PubMed: PMID 28100265 · NCT06337331 · Leukemia, Myeloid, Acute
  3. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.
    Lindsley RC, Saber W, Mar BG, et al. · N Engl J Med · 2017 · Trial result
    PubMed: PMID 28177873 · NCT06337331 · Leukemia, Myeloid, Acute
  4. The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2.
    Hartwig T, Montinaro A, von Karstedt S, et al. · Mol Cell · 2017 · Trial result
    PubMed: PMID 28212753 · NCT07511062 · Leukemia, Myeloid, Acute
  5. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
    Döhner H, Estey E, Grimwade D, et al. · Blood · 2017 · Trial result
    PubMed: PMID 27895058 · NCT04454580 · Leukemia, Myeloid, Acute
  6. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A, Berdeja JG, Patel MR, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 27049457 · NCT01742988 · Lymphoma, Large B-Cell, Diffuse
  7. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
    Kumar S, Kaufman JL, Gasparetto C, et al. · Blood · 2017 · Derived
    PubMed: PMID 29018077 · NCT01794520 · Multiple Myeloma
  8. Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis.
    Jones AK, Freise KJ, Agarwal SK, et al. · AAPS J · 2017 · Derived
    PubMed: PMID 27233802 · NCT02005471 (MURANO) · Leukemia, Lymphocytic, Chronic, B-Cell
  9. Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes.
    Yeh P, Dickinson M, Ftouni S, et al. · Blood · 2017 · Background
    PubMed: PMID 28126926 · NCT07060001 · Leukemia, Myeloid, Acute
  10. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.
    van der Sluis IM, Vrooman LM, Pieters R, et al. · Haematologica · 2017 · Background
    PubMed: PMID 26928249 · NCT04666649 · Leukemia, Myeloid, Acute
  11. Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species.
    Um HD · Oncotarget · 2017 · Background
    PubMed: PMID 26621844 · NCT07507825 (VHAG) · Leukemia, Myeloid, Acute
  12. Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes.
    Suzuki Y, Tomita A, Nakamura F, et al. · Cancer Sci · 2017 · Background
    PubMed: PMID 27323954 · NCT07060001 · Leukemia, Myeloid, Acute
  13. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
    Stilgenbauer S, Eichhorst B, Schetelig J, et al. · Lancet Oncol · 2017 · Background
    PubMed: PMID 27178240 · NCT03986034 · Leukemia, Lymphocytic, Chronic, B-Cell
  14. Cancer Statistics, 2017.
    Siegel RL, Miller KD, Jemal A, et al. · CA Cancer J Clin · 2017 · Background
    PubMed: PMID 28055103 · NCT07507825 (VHAG) · Leukemia, Myeloid, Acute
  15. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group.
    Pieters R, de Groot-Kruseman H, Van der Velden V, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 27269950 · NCT06764238 (CCCG-I/HR-ALL) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  16. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
    Möricke A, Zimmermann M, Valsecchi MG, et al. · Blood · 2017 · Background
    PubMed: PMID 26888258 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  17. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
    Martin T, Baz R, Benson DM, et al. · Blood · 2017 · Background
    PubMed: PMID 28483761 · NCT06115135 · Multiple Myeloma
  18. DNA methylation in human epigenomes depends on local topology of CpG sites.
    Lövkvist C, Dodd IB, Sneppen K, et al. · Nucleic Acids Res · 2017 · Background
    PubMed: PMID 26932361 · NCT07060001 · Leukemia, Myeloid, Acute
  19. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.
    Liu Y, Easton J, Shao Y, et al. · Nat Genet · 2017 · Background
    PubMed: PMID 28671688 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  20. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
    Kumar S, Paiva B, Anderson KC, et al. · Lancet Oncol · 2017 · Background
    PubMed: PMID 27511158 · NCT03732703 (MyDRUG) · Multiple Myeloma
  21. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.
    Konopleva M, Pollyea DA, Potluri J, et al. · Cancer Discov · 2017 · Background
    PubMed: PMID 27520294 · NCT04666649 · Leukemia, Myeloid, Acute
  22. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
    Kantarjian H, Stein A, Gökbuget N, et al. · N Engl J Med · 2017 · Background
    PubMed: PMID 28249141 · NCT06554626 · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  23. A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations.
    Han D, Lu X, Shih AH, et al. · Mol Cell · 2017 · Background
    PubMed: PMID 27477909 · NCT07060001 · Leukemia, Myeloid, Acute
  24. The genetics and molecular biology of T-ALL.
    Girardi T, Vicente C, Cools J, et al. · Blood · 2017 · Background
    PubMed: PMID 28115373 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  25. 'Acute myeloid leukemia: a comprehensive review and 2016 update'.
    De Kouchkovsky I, Abdul-Hay M · Blood Cancer J · 2017 · Background
    PubMed: PMID 27367478 · NCT06483906 · Leukemia, Myeloid, Acute
  26. Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.
    Camus V, Stamatoullas A, Mareschal S, et al. · Haematologica · 2017 · Background
    PubMed: PMID 27479820 · NCT07060001 · Leukemia, Myeloid, Acute
  27. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
    Bose P, Vachhani P, Cortes JE, et al. · Curr Treat Options Oncol · 2017 · Background
    PubMed: PMID 28286924 · NCT04666649 · Leukemia, Myeloid, Acute
  28. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.
    Barf T, Covey T, Izumi R, et al. · J Pharmacol Exp Ther · 2017 · Background
    PubMed: PMID 28882879 · NCT03868722
  29. Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax.
    Bajpai R, Matulis SM, Wei C, et al. · Oncogene · 2017 · Background
    PubMed: PMID 26640142 · NCT04666649 · Leukemia, Myeloid, Acute
  30. Deep Sequencing of Cell-Free Peripheral Blood DNA as a Reliable Method for Confirming the Diagnosis of Myelodysplastic Syndrome.
    Albitar F, Ma W, Diep K, et al. · Genet Test Mol Biomarkers · 2017 · Background
    PubMed: PMID 27248906 · NCT07060001 · Leukemia, Myeloid, Acute

2016 (16 papers)

  1. Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia.
    Sun H, Li Y, Zhang ZF, et al. · Int J Hematol · 2016 · Trial result
    PubMed: PMID 26358057 · NCT07511062 · Leukemia, Myeloid, Acute
  2. Macrophage Akt1 Kinase-Mediated Mitophagy Modulates Apoptosis Resistance and Pulmonary Fibrosis.
    Larson-Casey JL, Deshane JS, Ryan AJ, et al. · Immunity · 2016 · Trial result
    PubMed: PMID 26921108 · NCT05976217 · Idiopathic Pulmonary Fibrosis
  3. Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia.
    Yu C, Kong QL, Zhang YX, et al. · J Hematol Oncol · 2016 · Background
    PubMed: PMID 25957890 · NCT06652685 · Leukemia, Myeloid, Acute
  4. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
    Roberts AW, Davids MS, Pagel JM, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 26639348 · NCT03986034 · Leukemia, Lymphocytic, Chronic, B-Cell
  5. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ravandi F, O'Brien SM, Cortes JE, et al. · Cancer · 2016 · Background
    PubMed: PMID 26308885 · NCT06754267 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  6. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial.
    Rambaldi A, Grassi A, Masciulli A, et al. · Lancet Oncol · 2016 · Background
    PubMed: PMID 26429297 · NCT07052422
  7. Chronic lymphocytic leukemia (CLL)-Then and now.
    Rai KR, Jain P · Am J Hematol · 2016 · Background
    PubMed: PMID 26690614 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell
  8. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.
    Maury S, Chevret S, Thomas X, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 27626518 · NCT06387121 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  9. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
    Kantarjian HM, DeAngelo DJ, Stelljes M, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 27292104 · NCT06554626 · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  10. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells.
    Johnson-Farley N, Veliz J, Bhagavathi S, et al. · Leuk Lymphoma · 2016 · Background
    PubMed: PMID 25373508 · NCT05628623 (ERASE) · Leukemia, Myeloid, Acute
  11. Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia.
    Emadi A, Bade NA, Stevenson B, et al. · Pharmaceuticals (Basel) · 2016 · Background
    PubMed: PMID 27064021 · NCT04666649 · Leukemia, Myeloid, Acute
  12. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.
    Devine SM, Owzar K, Blum W, et al. · J Clin Oncol · 2016 · Background
    PubMed: PMID 26527780 · NCT07052422
  13. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.
    Chonghaile TN, Roderick JE, Glenfield C, et al. · Cancer Discov · 2016 · Background
    PubMed: PMID 24994123 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  14. Loss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer.
    Chen K, Zhang J, Guo Z, et al. · Cell Res · 2016 · Background
    PubMed: PMID 26680004 · NCT07060001 · Leukemia, Myeloid, Acute
  15. Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis.
    Bohers E, Viailly PJ, Dubois S, et al. · Haematologica · 2016 · Background
    PubMed: PMID 25749829 · NCT07060001 · Leukemia, Myeloid, Acute
  16. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
    Araki D, Wood BL, Othus M, et al. · J Clin Oncol · 2016 · Background
    PubMed: PMID 26668349 · NCT05628623 (ERASE) · Leukemia, Myeloid, Acute

2015 (19 papers)

  1. Molecular pathways: myeloid complicity in cancer.
    Stromnes IM, Greenberg PD, Hingorani SR, et al. · Clin Cancer Res · 2015 · Trial result
    PubMed: PMID 25047706 · NCT07511062 · Leukemia, Myeloid, Acute
  2. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States.
    Medeiros BC, Satram-Hoang S, Hurst D, et al. · Ann Hematol · 2015 · Trial result
    PubMed: PMID 25791241 · NCT06337331 · Leukemia, Myeloid, Acute
  3. Modulation of the mevalonate pathway by akt regulates macrophage survival and development of pulmonary fibrosis.
    Larson-Casey JL, Murthy S, Ryan AJ, et al. · J Biol Chem · 2015 · Trial result
    PubMed: PMID 25378391 · NCT05976217 · Idiopathic Pulmonary Fibrosis
  4. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease.
    Alexander KA, Flynn R, Lineburg KE, et al. · J Clin Invest · 2015 · Trial result
    PubMed: PMID 25157821 · NCT07511062 · Leukemia, Myeloid, Acute
  5. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.
    Saunthararajah Y, Sekeres M, Advani A, et al. · J Clin Invest · 2015 · Background
    PubMed: PMID 25621498 · NCT07283094 (FHD-286) · Leukemia, Myeloid, Acute
  6. Quantitative detection of circulating nucleophosmin mutations DNA in the plasma of patients with acute myeloid leukemia.
    Quan J, Gao YJ, Yang ZL, et al. · Int J Med Sci · 2015 · Background
    PubMed: PMID 25552914 · NCT07060001 · Leukemia, Myeloid, Acute
  7. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.
    Pui CH, Yang JJ, Hunger SP, et al. · J Clin Oncol · 2015 · Background
    PubMed: PMID 26304874 · NCT06387121 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  8. Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis.
    Percival ME, Tao L, Medeiros BC, et al. · Cancer · 2015 · Background
    PubMed: PMID 25739348 · NCT06483906 · Leukemia, Myeloid, Acute
  9. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.
    Peirs S, Matthijssens F, Goossens S, et al. · Blood · 2015 · Background
    PubMed: PMID 25301704 · NCT06742463 · Recurrence
  10. Characterization of acute myeloid leukemia based on levels of global hydroxymethylation.
    Kroeze LI, Aslanyan MG, van Rooij A, et al. · Blood · 2015 · Background
    PubMed: PMID 24986689 · NCT07060001 · Leukemia, Myeloid, Acute
  11. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
    Kim DY, Joo YD, Lim SN, et al. · Blood · 2015 · Background
    PubMed: PMID 26065651 · NCT06754267 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  12. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
    Jacque N, Ronchetti AM, Larrue C, et al. · Blood · 2015 · Background
    PubMed: PMID 26186940 · NCT04666649 · Leukemia, Myeloid, Acute
  13. Acute Lymphoblastic Leukemia in Children.
    Hunger SP, Mullighan CG · N Engl J Med · 2015 · Background
    PubMed: PMID 26465987 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  14. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
    Farooqui MZ, Valdez J, Martyr S, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 25555420 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell
  15. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
    Dombret H, Seymour JF, Butrym A, et al. · Blood · 2015 · Background
    PubMed: PMID 25987659 · NCT07507825 (VHAG) · Leukemia, Myeloid, Acute
  16. Acute Myeloid Leukemia.
    Döhner H, Weisdorf DJ, Bloomfield CD, et al. · N Engl J Med · 2015 · Background
    PubMed: PMID 26376137 · NCT05048615 · Leukemia, Myeloid, Acute
  17. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Daver N, Thomas D, Ravandi F, et al. · Haematologica · 2015 · Background
    PubMed: PMID 25682595 · NCT06754267 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  18. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
    Cortes JE, Goldberg SL, Feldman EJ, et al. · Cancer · 2015 · Background
    PubMed: PMID 25223583 · NCT05628623 (ERASE) · Leukemia, Myeloid, Acute
  19. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
    Chien WW, Allas S, Rachinel N, et al. · Invest New Drugs · 2015 · Background
    PubMed: PMID 24829072 · NCT04666649 · Leukemia, Myeloid, Acute

2014 (20 papers)

  1. CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2/CCR2-dependent gene expression profile.
    Sierra-Filardi E, Nieto C, Domínguez-Soto A, et al. · J Immunol · 2014 · Trial result
    PubMed: PMID 24639350 · NCT07511062 · Leukemia, Myeloid, Acute
  2. Myeloid colony-stimulating factors as regulators of macrophage polarization.
    Hamilton TA, Zhao C, Pavicic PG, et al. · Front Immunol · 2014 · Trial result
    PubMed: PMID 25484881 · NCT07511062 · Leukemia, Myeloid, Acute
  3. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.
    Willems L, Jacque N, Jacquel A, et al. · Blood · 2014 · Background
    PubMed: PMID 24014241 · NCT04666649 · Leukemia, Myeloid, Acute
  4. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
    Vora A, Goulden N, Mitchell C, et al. · Lancet Oncol · 2014 · Background
    PubMed: PMID 24924991 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  5. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.
    Roboz GJ, Rosenblat T, Arellano M, et al. · J Clin Oncol · 2014 · Background
    PubMed: PMID 24841975 · NCT05362942 · Leukemia, Myeloid, Acute
  6. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
    Patrick K, Wade R, Goulden N, et al. · Br J Haematol · 2014 · Background
    PubMed: PMID 24708207 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  7. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.
    Pan R, Hogdal LJ, Benito JM, et al. · Cancer Discov · 2014 · Background
    PubMed: PMID 24346116 · NCT05628623 (ERASE) · Leukemia, Myeloid, Acute
  8. Homoharringtonine and omacetaxine for myeloid hematological malignancies.
    Lü S, Wang J · J Hematol Oncol · 2014 · Background
    PubMed: PMID 24387717 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  9. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.
    Liu X, Zhang G, Yi Y, et al. · Leuk Lymphoma · 2014 · Background
    PubMed: PMID 23432690 · NCT07060001 · Leukemia, Myeloid, Acute
  10. Estimation of the total population moving into and out of the 20 km evacuation zone during the Fukushima NPP accident as calculated using "Auto-GPS" mobile phone data.
    Hayano RS, Adachi R · Proc Jpn Acad Ser B Phys Biol Sci · 2014 · Background
    PubMed: PMID 23666090 · NCT07320235 (IMAGINE) · Leukemia, Myeloid, Acute
  11. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies.
    Hallek M · Blood · 2014 · Background
    PubMed: PMID 24065239 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell
  12. [National guidelines for the management of patients with chronic lymphocytic leukemia. Sociedad Espan˜ola de Hematologı´a y Hemoterapia and Grupo Espan˜ol de Leucemia Linfocı´tica Cro´ nica].
    García Marco JA, Giraldo Castellano P, López Jiménez J, et al. · Med Clin (Barc) · 2014 · Background
    PubMed: PMID 23830547 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell
  13. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.
    Freeman SD, Virgo P, Couzens S, et al. · J Clin Oncol · 2014 · Background
    PubMed: PMID 24062403 · NCT05628623 (ERASE) · Leukemia, Myeloid, Acute
  14. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.
    Fielding AK, Rowe JM, Buck G, et al. · Blood · 2014 · Background
    PubMed: PMID 24277073 · NCT06754267 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  15. Asparaginase in the treatment of non-ALL hematologic malignancies.
    Emadi A, Zokaee H, Sausville EA, et al. · Cancer Chemother Pharmacol · 2014 · Background
    PubMed: PMID 24515335 · NCT04666649 · Leukemia, Myeloid, Acute
  16. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.
    Emadi A, Jun SA, Tsukamoto T, et al. · Exp Hematol · 2014 · Background
    PubMed: PMID 24333121 · NCT04666649 · Leukemia, Myeloid, Acute
  17. Prognostic factors in hodgkin lymphoma.
    Cuccaro A, Bartolomei F, Cupelli E, et al. · Mediterr J Hematol Infect Dis · 2014 · Background
    PubMed: PMID 25045461 · NCT07060001 · Leukemia, Myeloid, Acute
  18. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts.
    Chiaretti S, Vitale A, Cazzaniga G, et al. · Haematologica · 2014 · Background
    PubMed: PMID 23716539 · NCT06742463 · Recurrence
  19. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.
    Cartron G, de Guibert S, Dilhuydy MS, et al. · Blood · 2014 · Background
    PubMed: PMID 25143487 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell
  20. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    Byrd JC, Brown JR, O'Brien S, et al. · N Engl J Med · 2014 · Background
    PubMed: PMID 24881631 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell

2013 (13 papers)

  1. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment.
    Mussai F, De Santo C, Abu-Dayyeh I, et al. · Blood · 2013 · Trial result
    PubMed: PMID 23733335 · NCT07511062 · Leukemia, Myeloid, Acute
  2. Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia.
    Mohr B, Schetelig J, Schäfer-Eckart K, et al. · Br J Haematol · 2013 · Trial result
    PubMed: PMID 23432431 · NCT06337331 · Leukemia, Myeloid, Acute
  3. Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission.
    Mawad R, Gooley TA, Sandhu V, et al. · J Clin Oncol · 2013 · Trial result
    PubMed: PMID 24062388 · NCT06337331 · Leukemia, Myeloid, Acute
  4. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.
    Tsao T, Shi Y, Kornblau S, et al. · Ann Hematol · 2013 · Background
    PubMed: PMID 22893484 · NCT04687761 · Leukemia, Myeloid, Acute
  5. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure.
    Thomas RL, Roberts DJ, Kubli DA, et al. · Genes Dev · 2013 · Background
    PubMed: PMID 23788623 · NCT04666649 · Leukemia, Myeloid, Acute
  6. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
    Terwijn M, van Putten WL, Kelder A, et al. · J Clin Oncol · 2013 · Background
    PubMed: PMID 24062400 · NCT05628623 (ERASE) · Leukemia, Myeloid, Acute
  7. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
    Souers AJ, Leverson JD, Boghaert ER, et al. · Nat Med · 2013 · Background
    PubMed: PMID 23291630 · NCT04666649 · Leukemia, Myeloid, Acute
  8. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
    Ravandi F, Jorgensen JL, Thomas DA, et al. · Blood · 2013 · Background
    PubMed: PMID 23836561 · NCT06754267 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  9. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial.
    Jin J, Wang JX, Chen FF, et al. · Lancet Oncol · 2013 · Background
    PubMed: PMID 23664707 · NCT05893472 · Leukemia, Myeloid, Acute
  10. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03.
    Escherich G, Zimmermann M, Janka-Schaub G, et al. · Pediatr Blood Cancer · 2013 · Background
    PubMed: PMID 22948968 · NCT06764238 (CCCG-I/HR-ALL) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  11. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
    Cortes JE, Kantarjian H, Foran JM, et al. · J Clin Oncol · 2013 · Background
    PubMed: PMID 24002496 · NCT04687761 · Leukemia, Myeloid, Acute
  12. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.
    Cancer Genome Atlas Research Network, Ley TJ, Miller C, et al. · N Engl J Med · 2013 · Background
    PubMed: PMID 23634996 · NCT07060001 · Leukemia, Myeloid, Acute
  13. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma.
    Armand P, Oki Y, Neuberg DS, et al. · Br J Haematol · 2013 · Background
    PubMed: PMID 23795711 · NCT07060001 · Leukemia, Myeloid, Acute

2012 (12 papers)

  1. Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-.
    Middeke JM, Beelen D, Stadler M, et al. · Blood · 2012 · Trial result
    PubMed: PMID 22855604 · NCT06337331 · Leukemia, Myeloid, Acute
  2. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories.
    Cornelissen JJ, Breems D, van Putten WL, et al. · J Clin Oncol · 2012 · Trial result
    PubMed: PMID 22564995 · NCT06337331 · Leukemia, Myeloid, Acute
  3. Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma.
    Soucek L, Buggy JJ, Kortlever R, et al. · Neoplasia · 2012 · Background
    PubMed: PMID 22131884 · NCT03868722
  4. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Ponader S, Chen SS, Buggy JJ, et al. · Blood · 2012 · Background
    PubMed: PMID 22180443 · NCT03868722
  5. Treatment decisions for elderly patients with haematological malignancies: a dilemma.
    Peyrade F, Gastaud L, Ré D, et al. · Lancet Oncol · 2012 · Background
    PubMed: PMID 22846839 · NCT07469046 · Leukemia, Myeloid, Acute
  6. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
    Kantarjian HM, Thomas XG, Dmoszynska A, et al. · J Clin Oncol · 2012 · Background
    PubMed: PMID 22689805 · NCT07507825 (VHAG) · Leukemia, Myeloid, Acute
  7. Using peripheral blood circulating DNAs to detect CpG global methylation status and genetic mutations in patients with myelodysplastic syndrome.
    Iriyama C, Tomita A, Hoshino H, et al. · Biochem Biophys Res Commun · 2012 · Background
    PubMed: PMID 22382018 · NCT07060001 · Leukemia, Myeloid, Acute
  8. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.
    Hunger SP, Lu X, Devidas M, et al. · J Clin Oncol · 2012 · Background
    PubMed: PMID 22412151 · NCT06764238 (CCCG-I/HR-ALL) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  9. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).
    Herdman M, Gudex C, Lloyd A, et al. · Qual Life Res · 2012 · Background
    PubMed: PMID 21479777 · NCT04687761 · Leukemia, Myeloid, Acute
  10. Translation regulation as a therapeutic target in cancer.
    Grzmil M, Hemmings BA · Cancer Res · 2012 · Background
    PubMed: PMID 22850420 · NCT04666649 · Leukemia, Myeloid, Acute
  11. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
    de Rooij MF, Kuil A, Geest CR, et al. · Blood · 2012 · Background
    PubMed: PMID 22279054 · NCT03868722
  12. Targeting the B-cell lymphoma/leukemia 2 family in cancer.
    Davids MS, Letai A · J Clin Oncol · 2012 · Background
    PubMed: PMID 22649144 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma

2011 (11 papers)

  1. Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial.
    Stelljes M, Beelen DW, Braess J, et al. · Haematologica · 2011 · Trial result
    PubMed: PMID 21459795 · NCT06337331 · Leukemia, Myeloid, Acute
  2. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.
    Qian BZ, Li J, Zhang H, et al. · Nature · 2011 · Trial result
    PubMed: PMID 21654748 · NCT07511062 · Leukemia, Myeloid, Acute
  3. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.
    Kantarjian H, Ravandi F, O'Brien S, et al. · Blood · 2011 · Trial result
    PubMed: PMID 20668231 · NCT04454580 · Leukemia, Myeloid, Acute
  4. Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation.
    Fang M, Storer B, Estey E, et al. · Blood · 2011 · Trial result
    PubMed: PMID 21680797 · NCT06337331 · Leukemia, Myeloid, Acute
  5. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.
    Schrappe M, Valsecchi MG, Bartram CR, et al. · Blood · 2011 · Background
    PubMed: PMID 21719599 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  6. Acute myeloid leukaemia in the elderly: a review.
    Pollyea DA, Kohrt HE, Medeiros BC, et al. · Br J Haematol · 2011 · Background
    PubMed: PMID 21314823 · NCT07507825 (VHAG) · Leukemia, Myeloid, Acute
  7. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia.
    Lee JH, Joo YD, Kim H, et al. · Blood · 2011 · Background
    PubMed: PMID 21828126 · NCT06483906 · Leukemia, Myeloid, Acute
  8. Genomic 5-hydroxymethylcytosine levels correlate with TET2 mutations and a distinct global gene expression pattern in secondary acute myeloid leukemia.
    Konstandin N, Bultmann S, Szwagierczak A, et al. · Leukemia · 2011 · Background
    PubMed: PMID 21625234 · NCT07060001 · Leukemia, Myeloid, Acute
  9. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
    Ko M, Huang Y, Jankowska AM, et al. · Nature · 2011 · Background
    PubMed: PMID 21057493 · NCT07060001 · Leukemia, Myeloid, Acute
  10. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.
    Chen R, Guo L, Chen Y, et al. · Blood · 2011 · Background
    PubMed: PMID 20971952 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  11. Therapeutic advances in acute myeloid leukemia.
    Burnett A, Wetzler M, Löwenberg B, et al. · J Clin Oncol · 2011 · Background
    PubMed: PMID 21220605 · NCT05362942 · Leukemia, Myeloid, Acute

2010 (10 papers)

  1. Cell signaling by receptor tyrosine kinases.
    Lemmon MA, Schlessinger J · Cell · 2010 · Trial result
    PubMed: PMID 20602996 · NCT07511062 · Leukemia, Myeloid, Acute
  2. Access to hematopoietic stem cell transplantation: effect of race and sex.
    Joshua TV, Rizzo JD, Zhang MJ, et al. · Cancer · 2010 · Trial result
    PubMed: PMID 20564154 · NCT06337331 · Leukemia, Myeloid, Acute
  3. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment.
    Corzo CA, Condamine T, Lu L, et al. · J Exp Med · 2010 · Trial result
    PubMed: PMID 20876310 · NCT07511062 · Leukemia, Myeloid, Acute
  4. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.
    Yecies D, Carlson NE, Deng J, et al. · Blood · 2010 · Background
    PubMed: PMID 20197552 · NCT04666649 · Leukemia, Myeloid, Acute
  5. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
    Vrooman LM, Supko JG, Neuberg DS, et al. · Pediatr Blood Cancer · 2010 · Background
    PubMed: PMID 19672973 · NCT04666649 · Leukemia, Myeloid, Acute
  6. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.
    Pautas C, Merabet F, Thomas X, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 20048183 · NCT07060001 · Leukemia, Myeloid, Acute
  7. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
    Krug U, Röllig C, Koschmieder A, et al. · Lancet · 2010 · Background
    PubMed: PMID 21131036 · NCT07060001 · Leukemia, Myeloid, Acute
  8. [Revision arthroplasty of the hip: acetabular component].
    Gollwitzer H, von Eisenhart-Rothe R, Holzapfel BM, et al. · Chirurg · 2010 · Background
    PubMed: PMID 20232028 · NCT07320235 (IMAGINE) · Leukemia, Myeloid, Acute
  9. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
    Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 20026804 · NCT04687761 · Leukemia, Myeloid, Acute
  10. The Src, Syk, and Tec family kinases: distinct types of molecular switches.
    Bradshaw JM · Cell Signal · 2010 · Background
    PubMed: PMID 20206686 · NCT03868722

2009 (11 papers)

  1. The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia.
    Seifert H, Mohr B, Thiede C, et al. · Leukemia · 2009 · Trial result
    PubMed: PMID 19151774 · NCT06337331 · Leukemia, Myeloid, Acute
  2. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis.
    Bowen D, Groves MJ, Burnett AK, et al. · Leukemia · 2009 · Trial result
    PubMed: PMID 18596741 · NCT06337331 · Leukemia, Myeloid, Acute
  3. Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes.
    Vick B, Weber A, Urbanik T, et al. · Hepatology · 2009 · Background
    PubMed: PMID 19127517 · NCT04666649 · Leukemia, Myeloid, Acute
  4. Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia.
    Schwarz AK, Stanulla M, Cario G, et al. · Ann Hematol · 2009 · Background
    PubMed: PMID 19165483 · NCT07060001 · Leukemia, Myeloid, Acute
  5. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors.
    Montesinos P, Bergua JM, Vellenga E, et al. · Blood · 2009 · Background
    PubMed: PMID 18945964 · NCT07283094 (FHD-286) · Leukemia, Myeloid, Acute
  6. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain.
    Mohamed AJ, Yu L, Bäckesjö CM, et al. · Immunol Rev · 2009 · Background
    PubMed: PMID 19290921 · NCT03868722
  7. ICSH guidelines for the standardization of bone marrow specimens and reports.
    Lee SH, Erber WN, Porwit A, et al. · Int J Lab Hematol · 2009 · Background
    PubMed: PMID 18822060 · NCT07283094 (FHD-286) · Leukemia, Myeloid, Acute
  8. Dose escalation methods in phase I cancer clinical trials.
    Le Tourneau C, Lee JJ, Siu LL, et al. · J Natl Cancer Inst · 2009 · Background
    PubMed: PMID 19436029 · NCT04666649 · Leukemia, Myeloid, Acute
  9. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.
    Juliusson G, Antunovic P, Derolf A, et al. · Blood · 2009 · Background
    PubMed: PMID 19008455 · NCT04687761 · Leukemia, Myeloid, Acute
  10. Anthracycline dose intensification in acute myeloid leukemia.
    Fernandez HF, Sun Z, Yao X, et al. · N Engl J Med · 2009 · Background
    PubMed: PMID 19776406 · NCT04666649 · Leukemia, Myeloid, Acute
  11. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.
    Coustan-Smith E, Mullighan CG, Onciu M, et al. · Lancet Oncol · 2009 · Background
    PubMed: PMID 19147408 · NCT06855810 (CCCG-TALL-2025) · Precursor Cell Lymphoblastic Leukemia-Lymphoma

2008 (6 papers)

  1. Dissecting eIF4E action in tumorigenesis.
    Wendel HG, Silva RL, Malina A, et al. · Genes Dev · 2008 · Background
    PubMed: PMID 18055695 · NCT04666649 · Leukemia, Myeloid, Acute
  2. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.
    O'Brien S, Thomas DA, Ravandi F, et al. · Cancer · 2008 · Background
    PubMed: PMID 18720356 · NCT06387121 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  3. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model.
    Montesinos P, Lorenzo I, Martín G, et al. · Haematologica · 2008 · Background
    PubMed: PMID 18166787 · NCT04687761 · Leukemia, Myeloid, Acute
  4. Improved survival in multiple myeloma and the impact of novel therapies.
    Kumar SK, Rajkumar SV, Dispenzieri A, et al. · Blood · 2008 · Background
    PubMed: PMID 17975015 · NCT06115135 · Multiple Myeloma
  5. Telomerase and cancer therapeutics.
    Harley CB · Nat Rev Cancer · 2008 · Background
    PubMed: PMID 18256617 · NCT07320235 (IMAGINE) · Leukemia, Myeloid, Acute
  6. Acute myeloid leukemia in the elderly.
    Dombret H, Raffoux E, Gardin C, et al. · Semin Oncol · 2008 · Background
    PubMed: PMID 18692693 · NCT07507825 (VHAG) · Leukemia, Myeloid, Acute

2007 (5 papers)

  1. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Estey E, de Lima M, Tibes R, et al. · Blood · 2007 · Trial result
    PubMed: PMID 17038533 · NCT06337331 · Leukemia, Myeloid, Acute
  2. Effect of cytarabine and decitabine in combination in human leukemic cell lines.
    Qin T, Youssef EM, Jelinek J, et al. · Clin Cancer Res · 2007 · Background
    PubMed: PMID 17634552 · NCT05362942 · Leukemia, Myeloid, Acute
  3. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.
    Konopleva M, Contractor R, Tsao T, et al. · Cancer Cell · 2007 · Background
    PubMed: PMID 17097560 · NCT04687761 · Leukemia, Myeloid, Acute
  4. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.
    Deng J, Carlson N, Takeyama K, et al. · Cancer Cell · 2007 · Background
    PubMed: PMID 17692808 · NCT04666649 · Leukemia, Myeloid, Acute
  5. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.
    Burnett AK, Milligan D, Prentice AG, et al. · Cancer · 2007 · Background
    PubMed: PMID 17315155 · NCT04687761 · Leukemia, Myeloid, Acute

2006 (7 papers)

  1. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells.
    Tang R, Faussat AM, Majdak P, et al. · Mol Cancer Ther · 2006 · Background
    PubMed: PMID 16546987 · NCT06483906 · Leukemia, Myeloid, Acute
  2. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
    Smith TJ, Khatcheressian J, Lyman GH, et al. · J Clin Oncol · 2006 · Background
    PubMed: PMID 16682719 · NCT03868722
  3. Cyclin-dependent kinase pathways as targets for cancer treatment.
    Shapiro GI · J Clin Oncol · 2006 · Background
    PubMed: PMID 16603719 · NCT04687761 · Leukemia, Myeloid, Acute
  4. Targeting the cell cycle: a new approach to cancer therapy.
    Schwartz GK, Shah MA · J Clin Oncol · 2006 · Background
    PubMed: PMID 16361640 · NCT04687761 · Leukemia, Myeloid, Acute
  5. Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy.
    Kasperczyk H, La Ferla-Brühl K, Westhoff MA, et al. · Oncogene · 2006 · Background
    PubMed: PMID 16007147 · NCT07320235 (IMAGINE) · Leukemia, Myeloid, Acute
  6. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia.
    Buccisano F, Maurillo L, Gattei V, et al. · Leukemia · 2006 · Background
    PubMed: PMID 16838027 · NCT05628623 (ERASE) · Leukemia, Myeloid, Acute
  7. Age and acute myeloid leukemia.
    Appelbaum FR, Gundacker H, Head DR, et al. · Blood · 2006 · Background
    PubMed: PMID 16455952 · NCT07060001 · Leukemia, Myeloid, Acute

2005 (3 papers)

  1. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile.
    Schoch C, Kern W, Kohlmann A, et al. · Genes Chromosomes Cancer · 2005 · Background
    PubMed: PMID 15846790 · NCT04666649 · Leukemia, Myeloid, Acute
  2. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells.
    Opferman JT, Iwasaki H, Ong CC, et al. · Science · 2005 · Background
    PubMed: PMID 15718471 · NCT04666649 · Leukemia, Myeloid, Acute
  3. Prognostic index for adult patients with acute myeloid leukemia in first relapse.
    Breems DA, Van Putten WL, Huijgens PC, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 15632409 · NCT05362942 · Leukemia, Myeloid, Acute

2004 (2 papers)

  1. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia.
    Creutzig U, Kaspers GJ · J Clin Oncol · 2004 · Background
    PubMed: PMID 15310791 · NCT04687761 · Leukemia, Myeloid, Acute
  2. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
    Cheson BD, Bennett JM, Kopecky KJ, et al. · J Clin Oncol · 2004 · Background
    PubMed: PMID 14673054 · NCT04687761 · Leukemia, Myeloid, Acute

2003 (4 papers)

  1. CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor alpha and estrogen receptor beta expressions.
    Sasaki M, Tanaka Y, Kaneuchi M, et al. · Cancer Res · 2003 · Background
    PubMed: PMID 12873984 · NCT07320235 (IMAGINE) · Leukemia, Myeloid, Acute
  2. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML).
    Del Poeta G, Venditti A, Del Principe MI, et al. · Blood · 2003 · Background
    PubMed: PMID 12424199 · NCT05893472 · Leukemia, Myeloid, Acute
  3. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
    Byrd JC, Mrózek K, Dodge RK, et al. · Blood · 2003 · Background
    PubMed: PMID 12393746 · NCT04666649 · Leukemia, Myeloid, Acute
  4. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials.
    Boissel N, Auclerc MF, Lhéritier V, et al. · J Clin Oncol · 2003 · Background
    PubMed: PMID 12610173 · NCT06387121 · Precursor Cell Lymphoblastic Leukemia-Lymphoma

2002 (4 papers)

  1. The outcomes and costs of acute myeloid leukemia among the elderly.
    Menzin J, Lang K, Earle CC, et al. · Arch Intern Med · 2002 · Background
    PubMed: PMID 12123403 · NCT04687761 · Leukemia, Myeloid, Acute
  2. Telomerase is not an oncogene.
    Harley CB · Oncogene · 2002 · Background
    PubMed: PMID 11850774 · NCT07320235 (IMAGINE) · Leukemia, Myeloid, Acute
  3. Glutamine protects activated human T cells from apoptosis by up-regulating glutathione and Bcl-2 levels.
    Chang WK, Yang KD, Chuang H, et al. · Clin Immunol · 2002 · Background
    PubMed: PMID 12165276 · NCT04666649 · Leukemia, Myeloid, Acute
  4. Acute myeloid leukemia: treatment of adults under 60 years.
    Burnett AK · Rev Clin Exp Hematol · 2002 · Background
    PubMed: PMID 12060482 · NCT05362942 · Leukemia, Myeloid, Acute

2001 (3 papers)

  1. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.
    Slovak ML, Kopecky KJ, Cassileth PA, et al. · Blood · 2001 · Background
    PubMed: PMID 11110676 · NCT04666649 · Leukemia, Myeloid, Acute
  2. Telomeres and their control.
    McEachern MJ, Krauskopf A, Blackburn EH, et al. · Annu Rev Genet · 2001 · Background
    PubMed: PMID 11092831 · NCT07320235 (IMAGINE) · Leukemia, Myeloid, Acute
  3. Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase.
    Khan WN · Immunol Res · 2001 · Background
    PubMed: PMID 11444380 · NCT03868722

1999 (3 papers)

  1. Treatment of myeloma.
    Smith ML, Newland AC · QJM · 1999 · Background
    PubMed: PMID 10209667 · NCT06115135 · Multiple Myeloma
  2. Tossing monkey wrenches into the clock: new ways of treating cancer.
    Lees JA, Weinberg RA · Proc Natl Acad Sci U S A · 1999 · Background
    PubMed: PMID 10200241 · NCT04687761 · Leukemia, Myeloid, Acute
  3. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists.
    Chen YN, Sharma SK, Ramsey TM, et al. · Proc Natl Acad Sci U S A · 1999 · Background
    PubMed: PMID 10200261 · NCT04687761 · Leukemia, Myeloid, Acute

1998 (5 papers)

  1. Chromosome studies on normal and leukemic human leukocytes.
    NOWELL PC, HUNGERFORD DA · J Natl Cancer Inst · 1998 · Background
    PubMed: PMID 14427847 · NCT06754267 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  2. The serial cultivation of human diploid cell strains.
    HAYFLICK L, MOORHEAD PS · Exp Cell Res · 1998 · Background
    PubMed: PMID 13905658 · NCT07320235 (IMAGINE) · Leukemia, Myeloid, Acute
  3. Lymphomas associated with HIV infection.
    Diebold J, Raphael M, Prévot S, et al. · Cancer Surv · 1998 · Background
    PubMed: PMID 9547997 · NCT07320235 (IMAGINE) · Leukemia, Myeloid, Acute
  4. Extension of life-span by introduction of telomerase into normal human cells.
    Bodnar AG, Ouellette M, Frolkis M, et al. · Science · 1998 · Background
    PubMed: PMID 9454332 · NCT07320235 (IMAGINE) · Leukemia, Myeloid, Acute
  5. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD, Lawrence D, Byrd JC, et al. · Cancer Res · 1998 · Background
    PubMed: PMID 9751631 · NCT07060001 · Leukemia, Myeloid, Acute

1997 (1 paper)

  1. Replicative senescence and cell immortality: the role of telomeres and telomerase.
    Chiu CP, Harley CB · Proc Soc Exp Biol Med · 1997 · Background
    PubMed: PMID 9034126 · NCT07320235 (IMAGINE) · Leukemia, Myeloid, Acute

1996 (2 papers)

  1. Accelerated disappearance of melanocytes in bcl-2-deficient mice.
    Yamamura K, Kamada S, Ito S, et al. · Cancer Res · 1996 · Background
    PubMed: PMID 8758925 · NCT04687761 · Leukemia, Myeloid, Acute
  2. Telomerase activity in human germline and embryonic tissues and cells.
    Wright WE, Piatyszek MA, Rainey WE, et al. · Dev Genet · 1996 · Background
    PubMed: PMID 8934879 · NCT07320235 (IMAGINE) · Leukemia, Myeloid, Acute

1994 (5 papers)

  1. Hematopoietic receptors of class III receptor-type tyrosine kinases.
    Rosnet O, Birnbaum D · Crit Rev Oncog · 1994 · Trial result
    PubMed: PMID 7506935 · NCT07511062 · Leukemia, Myeloid, Acute
  2. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia.
    Vasioukhin V, Anker P, Maurice P, et al. · Br J Haematol · 1994 · Background
    PubMed: PMID 7918071 · NCT07060001 · Leukemia, Myeloid, Acute
  3. Targeted disruption of Bcl-2 alpha beta in mice: occurrence of gray hair, polycystic kidney disease, and lymphocytopenia.
    Nakayama K, Nakayama K, Negishi I, et al. · Proc Natl Acad Sci U S A · 1994 · Background
    PubMed: PMID 8170972 · NCT04687761 · Leukemia, Myeloid, Acute
  4. Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes.
    Moola ZB, Scawen MD, Atkinson T, et al. · Biochem J · 1994 · Background
    PubMed: PMID 7945221 · NCT04666649 · Leukemia, Myeloid, Acute
  5. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
    Mayer RJ, Davis RB, Schiffer CA, et al. · N Engl J Med · 1994 · Background
    PubMed: PMID 8078551 · NCT05628623 (ERASE) · Leukemia, Myeloid, Acute

1990 (1 paper)

  1. Telomeres shorten during ageing of human fibroblasts.
    Harley CB, Futcher AB, Greider CW, et al. · Nature · 1990 · Background
    PubMed: PMID 2342578 · NCT07320235 (IMAGINE) · Leukemia, Myeloid, Acute

1989 (1 paper)

  1. Design and analysis of phase I clinical trials.
    Storer BE · Biometrics · 1989 · Background
    PubMed: PMID 2790129 · NCT04666649 · Leukemia, Myeloid, Acute

1988 (1 paper)

  1. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study.
    Capizzi RL, Davis R, Powell B, et al. · J Clin Oncol · 1988 · Background
    PubMed: PMID 3162515 · NCT04666649 · Leukemia, Myeloid, Acute

1984 (1 paper)

  1. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.
    Groffen J, Stephenson JR, Heisterkamp N, et al. · Cell · 1984 · Background
    PubMed: PMID 6319012 · NCT06754267 · Precursor Cell Lymphoblastic Leukemia-Lymphoma

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).